var title_f14_57_15248="Infantile perianal pyramidal protrusion";
var content_f14_57_15248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile perianal pyramidal protrusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infantile perianal pyramidal protrusion is a pedunculated perineal lesion, typically located in the midline, just anterior to the anus. It occurs almost exclusively in girls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15248=[""].join("\n");
var outline_f14_57_15248=null;
var title_f14_57_15249="Parecoxib: International drug information";
var content_f14_57_15249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Parecoxib: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dynastat (AU, GB, IE, NO, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2205292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Parecoxib Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2205293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2205294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For the management of postoperative pain",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2210302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Adults &ge;18 years: 40 mg, followed by 20-40 mg every 6-12 hours; maximum daily dose: 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild (Child-Pugh score 5-6): No dosage adjustment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate (Child-Pugh score 7-9): 20 mg, followed by 20 mg every 6-12 hours; maximum daily dose: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe (Child-Pugh score &gt;9): Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2210303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution as sodium: 40 mg [package with diluent; strength expressed as base]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10477 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15249=[""].join("\n");
var outline_f14_57_15249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369734\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2205292\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2205293\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2205294\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2210302\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821133\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2210303\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15250="Anaphylaxis symptoms and diagnosis";
var content_f14_57_15250=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/57/15250/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15250/contributors\" id=\"au915\">",
"       F Estelle R Simons, MD, FRCPC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/57/15250/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15250/contributors\" id=\"se560\">",
"       Bruce S Bochner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/57/15250/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15250/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/57/15250?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Anaphylaxis is a potentially deadly allergic reaction that is rapid in onset. It is most often triggered by foods, medications, and insect stings. There are many other possible triggers.",
"    </p>",
"    <p>",
"     Anaphylaxis is an unpredictable condition. Many people who experience it have a known allergy and some have had one or more milder allergic reactions previously. Others, who are not even aware that they have an allergy, can suddenly experience severe anaphylaxis. Even the first episode of anaphylaxis can be fatal.",
"    </p>",
"    <p>",
"     The severity of anaphylactic reactions can be minimized by recognizing the symptoms early, having proper medication available for self-treatment, and seeking emergency medical care promptly. This topic reviews the symptoms and diagnosis of anaphylaxis. Treatment and prevention of anaphylaxis are discussed separately. A separate topic discusses how to use an epinephrine autoinjector. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"      \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of anaphylaxis generally begin within minutes to an hour of exposure to a trigger. Less commonly, symptoms do not develop for several hours.",
"    </p>",
"    <p>",
"     The most common symptoms of anaphylaxis are hives (urticaria) and swelling of the skin (angioedema), which occur in 80 to 90 percent of reactions. Respiratory symptoms occur in about 70 percent of reactions, and are especially common in people who also have asthma or another chronic respiratory disease. Extremely low blood pressure, causing lightheadedness, dizziness, blurred vision, or loss of consciousness (passing out) occurs in about 30 percent of reactions.",
"    </p>",
"    <p>",
"     Anaphylaxis can cause symptoms throughout the body:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Skin: Itching, flushing, hives (urticaria), or swelling (angioedema)",
"      </li>",
"      <li>",
"       Eyes: Itching, tearing, redness, or swelling of the skin around the eyes",
"      </li>",
"      <li>",
"       Nose and mouth: Sneezing, runny nose, nasal congestion, swelling of the tongue, or a metallic taste",
"      </li>",
"      <li>",
"       Lungs and throat: Difficulty getting air in or out, repeated coughing, chest tightness, wheezing or other sounds of labored breathing, increased mucus production, throat swelling or itching, hoarseness, change in voice, or a sensation of choking",
"      </li>",
"      <li>",
"       Heart and circulation: Dizziness, weakness, fainting, rapid, slow, or irregular heart rate, or low blood pressure",
"      </li>",
"      <li>",
"       Digestive system: Nausea, vomiting, abdominal cramps, or diarrhea",
"      </li>",
"      <li>",
"       Nervous system: Anxiety, confusion, or a sense of impending doom",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A severe form of anaphylaxis causes sudden collapse without other obvious symptoms, such as hives or flushing. This form of anaphylaxis occurs most commonly after a person is given a medication into a vein or is stung by an insect.",
"    </p>",
"    <p>",
"     Up to 20 percent of people with anaphylaxis have biphasic (two-phase) or protracted (prolonged) anaphylaxis. A person with biphasic anaphylaxis has a reaction that resolves and then recurs hours later without further exposure to the trigger. The late phase reaction usually occurs within eight hours, but may occur up to 72 hours after the initial symptoms. A person with protracted anaphylaxis has signs and symptoms that persist for hours or even days despite treatment, although this is rare.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS TRIGGERS",
"     </span>",
"    </p>",
"    <p>",
"     The trigger for a person's anaphylaxis may be obvious or it may be difficult to identify.",
"    </p>",
"    <p>",
"     Common anaphylaxis triggers can include (",
"     <a class=\"graphic graphic_figure graphicRef82830 \" href=\"UTD.htm?37/43/38586\">",
"      figure 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Foods: In children, hen's eggs, cow's milk, peanuts, tree nuts, fish, wheat, and soy are the most common food triggers.",
"       <br/>",
"       <br/>",
"       In teens and adults, peanuts, tree nuts, fish, and crustaceans (shellfish such as shrimp) are the most common triggers.",
"       <br/>",
"       <br/>",
"       Any food, including fruits and vegetables, and some spices and food additives, can cause anaphylaxis.",
"      </li>",
"      <li>",
"       Venom from insects, including bees, yellow jackets, wasps, hornets, and fire ants",
"      </li>",
"      <li>",
"       Venom from insects, including bees, hornets, wasps, and fire ants",
"      </li>",
"      <li>",
"       Latex from natural rubber, found in some latex gloves, balloons, condoms, sports equipment, and medical products",
"      </li>",
"      <li>",
"       Allergen immunotherapy (\"allergy shots\"), such as those given for the treatment of allergic rhinitis (hay fever)",
"      </li>",
"      <li>",
"       Exercise, either by itself, or after eating certain foods (eg, wheat, celery, seafood), medications (eg, aspirin), or exposure to cold",
"       <span class=\"nowrap\">",
"        air/water",
"       </span>",
"      </li>",
"      <li>",
"       Less common triggers include exposure to airborne allergens (such as horse dander), human seminal fluid, and cold temperatures.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Sometimes a specific trigger cannot be identified, even after a thorough evaluation. This condition is called idiopathic anaphylaxis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      IgE mediated anaphylaxis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most people, anaphylaxis is caused by the presence of proteins called immunoglobulin E (IgE) antibodies. IgE antibodies are normally produced in the body for the purpose of fighting certain infections. In people with allergies, however, IgE is made in response to non-infectious substances, such as foods, medications, or insect venoms. This IgE then sticks to the outside of mast cells and basophils, a type of white blood cell.",
"    </p>",
"    <p>",
"     If a person with IgE antibodies to a specific allergen is exposed to that allergen again, the cells may suddenly become activated. The activated cells release large amounts of inflammation-causing chemicals (including histamine) into the blood stream, causing anaphylaxis.",
"    </p>",
"    <p>",
"     The chemicals released from the cells cause the signs and symptoms typical of anaphylaxis. (See",
"     <a class=\"local\" href=\"#H2\">",
"      'Anaphylaxis symptoms'",
"     </a>",
"     above.) The allergic reaction can be so strong that it becomes life-threatening; for example, sudden severe swelling in the throat can lead to suffocation.",
"    </p>",
"    <p>",
"     In some people with anaphylaxis, the reaction is caused by a process that does not involve allergens and IgE. However, the symptoms and treatment are the same.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Some people are more likely than others to experience anaphylaxis or to develop severe symptoms during anaphylaxis, for example, those who have one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Previous sudden severe allergic reaction involving the whole body &mdash; People who have had allergic reactions to a particular substance in the past are at increased risk of anaphylaxis. However, the severity of past allergic reactions does not reliably predict the severity of future reactions; people with mild reactions in the past may experience severe anaphylactic reactions in the future.",
"      </li>",
"      <li>",
"       Asthma &mdash; People with asthma are more likely to have more severe respiratory problems during anaphylaxis. The combination of food allergy (especially to peanuts and tree nuts) and asthma seems to put people at risk for life-threatening episodes of anaphylaxis.",
"      </li>",
"      <li>",
"       Other diseases &mdash; People with chronic lung disease, especially older adults with chronic obstructive pulmonary disease (COPD) or emphysema, are at increased risk of complications during an anaphylactic reaction. People with coronary artery disease and other heart diseases are also at greater risk of developing complications during an anaphylactic reaction.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of anaphylaxis is based upon symptoms that occur suddenly after being exposed to a potential trigger, such as a food, medication, or insect sting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Is it anaphylaxis or another problem?",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other health problems can cause symptoms that are similar to those of anaphylaxis. These include a severe asthma attack, a heart attack, a panic attack, or even food poisoning. Evaluation by a specialist can help to clarify the diagnosis.",
"    </p>",
"    <p>",
"     Tryptase is a protein that is released into the blood during an anaphylactic reaction. An increased amount of tryptase can sometimes be measured in a blood sample collected during the first three hours after anaphylaxis symptoms have begun, eg, after a medication has been taken or after an insect sting. However, tryptase levels are seldom elevated in food-induced anaphylaxis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ANAPHYLAXIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment and prevention of anaphylaxis are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804618566\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12677109\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/42/25250?source=see_link\">",
"      Patient information: Insect allergy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/57/29586?source=see_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=see_link\">",
"      Patient information: Drug allergy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12677174\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"      Drug eruptions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"      Fatal anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients/gallery/anaphylaxis.asp\">",
"        www.aaaai.org/patients/gallery/anaphylaxis.asp",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acaai.org/allergist/allergies/Anaphylaxis/Pages/anaphylaxis-patient-tip-sheet.aspx\">",
"        www.acaai.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Anaphylaxis Foundation and Anaphylaxis Network of Canada",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.anaphylaxis.org/\">",
"        www.anaphylaxis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Anaphylaxis Campaign",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.anaphylaxis.org.uk/\">",
"        www.anaphylaxis.org.uk",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Food Allergy and Anaphylaxis Network",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.foodallergy.org/anaphylaxis/index.html\">",
"        www.foodallergy.org/anaphylaxis/index.html",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/57/15250/abstract/1\">",
"      1",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/57/15250?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15250/abstract/1\">",
"      Simons FE, Ardusso LR, Bil&ograve; MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_57_15250=[""].join("\n");
var outline_f14_57_15250=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANAPHYLAXIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ANAPHYLAXIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ANAPHYLAXIS TRIGGERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ANAPHYLAXIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ANAPHYLAXIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ANAPHYLAXIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/43/38586\" title=\"figure 1\">",
"           Anaphylaxis mechanisms and triggers",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15251="Long axis TOF VSD malalignment";
var content_f14_57_15251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1042px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/79575/Long_axis_TOF_VSD_mala.mp4?title=Long+axis+TOF+VSD+malalignment\" style=\"width:432px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Malalignment ventricular septal defect in a patient with tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from the accompanying echocardiographic video of the parasternal long axis view demonstrates the malalignment of the ventricular conal septum (CS) and trabecular septum (TS), which results in aortic override in a patient with TOF. In the video clip, cephalad angulation of the imaging transducer reveals the hypoplastic pulmonary artery.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle; LA: left atrium; Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15251=[""].join("\n");
var outline_f14_57_15251=null;
var title_f14_57_15252="Magnesium citrate: Patient drug information";
var content_f14_57_15252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Magnesium citrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     see \"Magnesium citrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34403?source=see_link\">",
"     see \"Magnesium citrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3884001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citroma&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Citro-Mag&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean out the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702430",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to magnesium citrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Appendicitis, colostomy, high blood sugar (diabetes), diverticulitis, ileostomy, bowel block, kidney failure, or ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chill the solution to make it taste better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695466",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water, fruit juice, or citrus flavored carbonated drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For hard stools (constipation), take as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11215 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15252=[""].join("\n");
var outline_f14_57_15252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3884001\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190827\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012385\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012384\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012389\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012390\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012392\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012387\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012388\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012393\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012394\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=related_link\">",
"      Magnesium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34403?source=related_link\">",
"      Magnesium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15253="Ferrous gluconate: Pediatric drug information";
var content_f14_57_15253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferrous gluconate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"    see \"Ferrous gluconate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42804?source=see_link\">",
"    see \"Ferrous gluconate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferate [OTC];",
"     </li>",
"     <li>",
"      Fergon&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ferrous Gluconate&reg;;",
"     </li>",
"     <li>",
"      Novo-Ferrogluc",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1013969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Iron Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineral, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1013993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=see_link\">",
"      see \"Ferrous gluconate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dose expressed in terms of",
"     <b>",
"      elemental",
"     </b>",
"     iron):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended Daily Allowance: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Recommended Daily Allowance of Iron:",
"      <b>",
"       (Dosage expressed as elemental iron)",
"      </b>",
"     </caption>",
"     <col align=\"left\" width=\"175\">",
"     </col>",
"     <col align=\"center\" width=\"175\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;5 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         5 mo to 10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Male",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Female",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         11-50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:2em;\">",
"         &gt;50 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Treatment and prevention of iron deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe iron deficiency anemia: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate iron deficiency anemia: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1-2 mg elemental iron/kg/day up to a maximum of 15 mg elemental iron/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Iron deficiency: 2-3 mg/kg/day or 60-100 mg elemental iron twice daily up to 60 mg elemental iron 4 times/day, or 50 mg elemental iron (extended release) 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 60-100 mg elemental iron/day",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Iron Content of Iron Salts",
"     </caption>",
"     <col align=\"left\" width=\"220\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Iron Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Iron Content",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (% of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of iron salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous fumarate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         197",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         560",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         324",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ferrous sulfate, exsiccated",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         217",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 246 mg [elemental iron 28 mg], 324 mg [elemental iron 38 mg], 325 mg [elemental iron 36 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferate: 240 mg [elemental iron 27 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fergon&reg;: 240 mg [elemental iron 27 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1013998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Do not chew or crush sustained release preparations; administer with water or juice between meals for maximum absorption; may administer with food if GI upset occurs; do not administer with milk or milk products",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1013970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron deficiency anemias; supplemental therapy for patients receiving epoetin alfa",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dark stools, diarrhea, heartburn, nausea, staining of teeth, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1013972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5262820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using for longer than 6 months, except in patients with conditions that require prolonged therapy; avoid in patients with peptic ulcer, enteritis, or ulcerative colitis; avoid in patients receiving frequent blood transfusions. Severe iron toxicity may occur in overdose, particularly when ingested by children; iron is a leading cause of fatal poisoning in children; store out of children's reach and in child-resistant containers. Liquid preparations may temporarily stain the teeth.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1013973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1013986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Milk, cereals, dietary fiber, tea, coffee, or eggs decrease absorption of iron.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1014000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum iron, total iron binding capacity, reticulocyte count, hemoglobin, ferritin",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1013990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 110-270 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 30-70 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 55-120 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Male: 75-175 mcg/dL; Female: 65-165 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 59-175 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 100-400 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iron levels &gt;300 mcg/dL may be considered toxic; should be treated as an overdosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ferritin: 13-300 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1013989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is released from the plasma and eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5262821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Peak reticulocytosis occurs in 5-10 days, and hemoglobin values increase within 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1013991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Iron is largely bound to serum transferrin and excreted in the urine, sweat, sloughing of intestinal mucosa, and by menses",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1014002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42804?source=see_link\">",
"      see \"Ferrous gluconate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color the stools and urine black; liquid preparations may temporarily stain the teeth; do not take within 2 hours of tetracyclines or fluoroquinolones, do not take with milk or antacids; keep out of reach of children",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5262822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When treating iron deficiency anemias, treat for 3-4 months after hemoglobin/hematocrit return to normal in order to replenish total body stores",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13055 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15253=[""].join("\n");
var outline_f14_57_15253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170834\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013969\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013993\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170819\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170804\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013998\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013970\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170868\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013972\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262820\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013973\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299323\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170813\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013986\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789289\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014000\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013990\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262821\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013991\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1014002\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5262822\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/37/38485?source=related_link\">",
"      Ferrous gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/51/42804?source=related_link\">",
"      Ferrous gluconate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15254="Hydralazine: Drug information";
var content_f14_57_15254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydralazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8837?source=see_link\">",
"    see \"Hydralazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"    see \"Hydralazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydralazine&reg;;",
"     </li>",
"     <li>",
"      Apresoline&reg;;",
"     </li>",
"     <li>",
"      Novo-Hylazin;",
"     </li>",
"     <li>",
"      Nu-Hydral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 10 mg 4 times/day; increase by 10-25 mg/dose every 2-5 days (maximum: 300 mg/day); usual dose range (JNC 7): 25-100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension:",
"     </b>",
"     I.M., I.V.: Initial: 10-20 mg/dose every 4-6 hours as needed, may increase to 40 mg/dose; change to oral therapy as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pre-eclampsia/eclampsia:",
"     </b>",
"     I.M., I.V.: 5 mg/dose then 5-10 mg every 20-30 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congestive heart failure:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     10-25 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     Dosage must be adjusted based on individual response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Target dose:",
"     </i>",
"     225-300 mg/day in divided doses; use in combination with isosorbide dinitrate",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"      see \"Hydralazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 0.75-1 mg/kg/day in 2-4 divided doses; increase over 3-4 weeks to maximum of 7.5 mg/kg/day in 2-4 divided doses; maximum daily dose: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute hypertension:",
"     </b>",
"     I.M., I.V.: 0.1-0.2 mg/kg/dose (not to exceed 20 mg) every 4-6 hours as needed, up to 1.7-3.5 mg/kg/day in 4-6 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 10 mg 2-3 times/day; increase by 10-25 mg/day every 2-5 days.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F179469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 8 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8-16 hours in fast acetylators and every 12-24 hours in slow acetylators.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis effects: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis effects: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, hydralazine undergoes extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 20 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F179440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solution for injection: Administer as a slow I.V. push; maximum rate: 5 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Caspofungin, heparin, hydrocortisone sodium succinate, potassium chloride, verapamil, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ampicillin, furosemide, nesiritide, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Nitroglycerin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Digoxin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7789435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart failure; hypertension secondary to pre-eclampsia/eclampsia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       HydrALAZINE may be confused with hydrOXYzine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F179497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, flushing, orthostatic hypotension, palpitations, paradoxical hypertension, peripheral edema, tachycardia, vascular collapse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression, disorientation, dizziness, fever, headache, increased intracranial pressure (I.V.; in patient with pre-existing increased intracranial pressure), psychotic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, nausea, paralytic ileus, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, erythrocyte count reduced, hemoglobin decreased, hemolytic anemia, leukopenia, thrombocytopenia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps, peripheral neuritis, rheumatoid arthritis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug-induced lupus-like syndrome (dose related; fever, arthralgia, splenomegaly, lymphadenopathy, asthenia, myalgia, malaise, pleuritic chest pain, edema, positive ANA, positive LE cells, maculopapular facial rash, positive direct Coombs' test, pericarditis, pericardial tamponade)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydralazine or any component of the formulation; mitral valve rheumatic heart disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-induced lupus-like syndrome: May cause a drug-induced lupus-like syndrome (more likely on larger doses, longer duration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/sodium retention: Hydralazine-induced fluid and sodium retention may require addition or increased dosage of a diuretics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuritis: Hydralazine has been associated with peripheral neuritis (eg, paresthesia, numbness, and tingling), possibly due to an antipyridoxine effect. Pyridoxine therapy should be initiated with onset of such symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease (CAD); increase in tachycardia may increase myocardial oxygen demand.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary hypertension: Use with caution in pulmonary hypertension; may cause hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Monitor blood pressure closely following I.V. administration. Response may be delayed and unpredictable in some patients; titrate cautiously to response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient compliance: Patients may be poorly compliant because of frequent dosing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F179495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F179460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food enhances bioavailability of hydralazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies at 20-30 times the maximun daily human dose. Hydralazine crosses the placenta. Hydralazine is recommended for use in the management of hypertension associated with pre-eclampsia.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F179473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F179447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a case report, following a maternal dose of hydralazine 50 mg three times daily, exposure to the infant was calculated to be 0.013 mg per 75 mL breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F179448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablet with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HydrALAZINE HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $14.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (HydrALAZINE HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $41.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $50.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $56.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $101.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F179435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (monitor closely with I.V. use), standing and sitting/supine, heart rate, ANA titer",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F179449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alphapress (AU);",
"     </li>",
"     <li>",
"      Aprelazine (TW);",
"     </li>",
"     <li>",
"      Apresol (IN);",
"     </li>",
"     <li>",
"      Apresolin (NO, SE, TR);",
"     </li>",
"     <li>",
"      Apresolina (MX, PT, UY, VE);",
"     </li>",
"     <li>",
"      Apresoline (AU, BB, BF, BJ, BM, BS, BZ, CI, ET, GB, GH, GM, GN, GY, IE, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, NZ, PH, SC, SD, SG, SL, SN, SR, TH, TN, TT, TW, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Aprezin (TW);",
"     </li>",
"     <li>",
"      Apulon (TW);",
"     </li>",
"     <li>",
"      Cesoline Y (TH);",
"     </li>",
"     <li>",
"      Cesoline-W (TH);",
"     </li>",
"     <li>",
"      Clorana (BR);",
"     </li>",
"     <li>",
"      Hidral (AR);",
"     </li>",
"     <li>",
"      Hydrapres (AR, ES);",
"     </li>",
"     <li>",
"      Hyperphen (ZA);",
"     </li>",
"     <li>",
"      Slow-Apresoline (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Stable (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F179425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct vasodilation of arterioles (with little effect on veins) with decreased systemic resistance",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F179443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 20-30 minutes; I.V.: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Up to 8 hours; I.V.: 1-4 hours;",
"     <b>",
"      Note:",
"     </b>",
"     May vary depending on acetylator status of patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically acetylated; extensive first-pass effect (oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 30% to 50%; increased with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 2-8 hours; End-stage renal disease: 7-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (14% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins--Obstetrics, \"ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Number 33, January 2002,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 99(1):159-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/16175681/pubmed\" id=\"16175681\" target=\"_blank\">",
"        16175681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Archibald DG, Ziesche S, et al, &ldquo;Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 314(24):1547-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/3520315/pubmed\" id=\"3520315\" target=\"_blank\">",
"        3520315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Johnson G, Ziesche S, et al, &ldquo;A Comparison of Enalapril With Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(5):303-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/2057035/pubmed\" id=\"2057035\" target=\"_blank\">",
"        2057035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liedholm H, W&aring;hlin-Boll E, Hanson A, et al, \"Transplacental Passage and Breast Milk Concentrations of Hydralazine,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1982, 21(5):417-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/7200428/pubmed\" id=\"7200428\" target=\"_blank\">",
"        7200428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE and Varon J, &ldquo;Hypertensive Crises: Challenges and Management,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6); 1949-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/17565029/pubmed\" id=\"17565029\" target=\"_blank\">",
"        17565029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AL, Ziesche S, Yancy C, et al, &ldquo;Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(20):2049-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/57/15254/abstract-text/15533851/pubmed\" id=\"15533851\" target=\"_blank\">",
"        15533851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8528 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15254=[""].join("\n");
var outline_f14_57_15254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179464\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179467\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179485\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179468\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179469\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897529\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179437\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179422\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179440\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179506\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179438\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7789435\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179508\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179444\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179426\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179495\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179431\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179460\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179433\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179473\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179447\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179448\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524631\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179435\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179449\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179425\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179443\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/40/8837?source=related_link\">",
"      Hydralazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=related_link\">",
"      Hydralazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15255="Q fever endocarditis";
var content_f14_57_15255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Q fever endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Didier Raoult, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15255/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/57/15255/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Q fever, a rickettsiosis due to Coxiella burnetii, is a zoonosis widespread throughout the world, which can present as acute or chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=see_link\">",
"     \"Microbiology and epidemiology of Q fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of intriguing aspects to this infection for which explanations remain obscure.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of the chronic form of the illness in some patients",
"     </li>",
"     <li>",
"      The specific increase in phase-I antibodies",
"     </li>",
"     <li>",
"      The inability of antibiotic treatment to eradicate the organism in less than one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endocarditis is the most serious and often fatal form of chronic Q fever. In one series, for example, the mortality was 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2\">",
"     2",
"    </a>",
"    ]. Diagnosing Q fever endocarditis is difficult and currently relies on nonspecific cardiac findings, evidence of liver involvement, and serologic tests. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because the clinical picture of the disease usually does not resemble classic endocarditis, the diagnosis is generally made because of previous valvular damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of Q fever endocarditis in patients with Q fever primarily occurs in patients with previous valvular disease or immunocompromise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This was illustrated by a retrospective study of 302 patients diagnosed with Q fever that investigated risk factors for developing endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexisting valvular disease was much more common in the 102 patients who developed endocarditis (93 versus 3 percent in those who did not develop endocarditis).",
"     </li>",
"     <li>",
"      Among the patients who had preexisting valve disease, the estimated risk of endocarditis was 39 percent.",
"     </li>",
"     <li>",
"      Among the seven patients with endocarditis but no valvulopathy, five had active cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients who develop Q fever endocarditis have clinically silent and previously undiagnosed valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, screening echocardiography may be warranted in patients with Q fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention or early diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Q fever endocarditis is a severe and often fatal disease that is the major manifestation of chronic Q fever. In a large retrospective study of patients seen between 1985 and 1998, 23 percent had chronic Q fever and endocarditis was the predominant manifestation in 77 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with Q fever endocarditis are men over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/8\">",
"     8",
"    </a>",
"    ], but women and children also develop this complication. An exposure factor such as professional contact with cattle is frequently found, but uncertainty about the incubation time and the usually long delay in diagnosis can mask important exposures.",
"   </p>",
"   <p>",
"    Most patients with Q fever endocarditis have preexisting valve disease (93 percent in a series of 102 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/3\">",
"     3",
"    </a>",
"    ]. The underlying heart disease may be congenital, rheumatic, degenerative, or syphilitic. The aortic and mitral valves are often involved, but 55 percent of patients in one report had prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no typical clinical presentation of Q fever endocarditis. Many patients have previously known valvulopathy and present with symptoms of heart failure or valve dysfunction or with constitutional symptoms, including fever, malaise, weakness, weight loss, fatigue, chills, anorexia, and night sweats [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Fever is present at the beginning of the disease in two-thirds of cases. It is usually low grade, waxes and wanes, and is well tolerated.",
"   </p>",
"   <p>",
"    The clinical manifestations and presentation of Q fever endocarditis may have changed over time, perhaps due to earlier diagnosis of the infection. One report compared a series of 15 patients with Q fever endocarditis from southern France in 1999 to 2000 to 15 patients from the same region published in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/10\">",
"     10",
"    </a>",
"    ]. The patients in the later series had a decreased interval to diagnosis of a mean of six months and were less likely to have heart failure or hepatomegaly, elevated erythrocyte sedimentation rate, or abnormal liver function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peripheral manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral manifestations of endocarditis are frequently found in Q fever, in contrast to most other causes of infective endocarditis. Common findings include splenomegaly (in approximately 50 percent), digital clubbing (33 percent) and a purpuric rash (20 percent). The rash generally occurs on the extremities and the mucosa (eg, conjunctivae). When biopsied, the purpuric lesions show an immune complex vasculitis.",
"   </p>",
"   <p>",
"    Hepatomegaly is also frequently seen. The liver is generally hard and often considerably enlarged. On liver biopsy, the fibrinoid ring surrounding the granuloma, as observed in acute Q fever hepatitis, has not been reported in endocarditis. Most cases of chronic hepatitis in Q fever are associated with valvular damage; thus, endocarditis should be suspected when diagnosing chronic Q fever hepatitis.",
"   </p>",
"   <p>",
"    Renal involvement, manifesting as microscopic hematuria, occurs in up to one-half of patients with endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/8\">",
"     8",
"    </a>",
"    ]. As in other forms of endocarditis, the most frequent pathologic finding is an immune complex glomerulonephritis, which, if the diagnosis is delayed, can lead to renal insufficiency. An immune complex glomerulonephritis can also occur in acute Q fever in the apparent absence of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=see_link\">",
"     \"Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Embolic manifestations occur in about 20 percent of patients and may be recurrent. The emboli can involve cerebral, arm, or leg vessels, and embolectomy or amputation may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary and pleural manifestations may be observed as a complication of Q fever endocarditis. Neurologic manifestations are rare except for embolic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common laboratory findings in Q fever endocarditis are largely nonspecific. The erythrocyte sedimentation rate is elevated in almost all patients and anemia, thrombocytopenia, and hematuria are each present in approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Other frequent findings include elevations in serum aminotransferases, lactate dehydrogenase, creatine phosphokinase, and globulins.",
"   </p>",
"   <p>",
"    Hyperglobulinemia may be helpful diagnostically, especially when the globulins represent more than 50 percent of the total protein concentration. The longer the diagnostic delay, the higher the globulin concentration will be.",
"   </p>",
"   <p>",
"    Rheumatoid factor, as detected by the latex test, is frequently present, as are circulating immune complexes and cryoglobulins. Antismooth muscle antibodies (in low titers), antiphospholipid antibodies, antimitochondrial antibodies, and a positive Coombs test also may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major components of the diagnosis of Q fever endocarditis: the diagnosis of Q fever, and the diagnosis of endocarditis.",
"   </p>",
"   <p>",
"    The diagnosis of endocarditis has often been made late because the symptoms are not specific for endocarditis, conventional blood cultures are negative, and vegetations are rarely seen by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/7\">",
"     7",
"    </a>",
"    ]. In a 1995 review, the mean reported interval from onset to diagnosis was 12 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/8\">",
"     8",
"    </a>",
"    ]. However, as noted above, the delay in diagnosis may have declined over time in association with less severe clinical manifestations (eg, less frequent heart failure or hepatomegaly) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Q fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important point in the diagnosis of Q fever endocarditis is to consider Q fever in all cases of blood culture-negative endocarditis. In two studies of suspected culture-negative endocarditis, C. burnetii was the most common pathogen identified (7 of 15 and 167 of 348 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of Q fever is confirmed by serologic testing for antibodies to phase-I and phase-II antigens. The most commonly used serologic technique is the microimmunofluorescence (MIF) test, which should distinguish between titers of IgG and IgM antibodies. A titer &ge;200 for IgG and &ge;50 for IgM against phase II indicates a recent Q fever infection, while an IgG titer &gt;800 against phase I suggests chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of Q fever\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In chronic Q fever endocarditis, there is a high antibody response to both phase I and phase II of the bacterium. An antiphase I IgG antibody titer &gt;800 indicates chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/15\">",
"     15",
"    </a>",
"    ]. The titers of IgM are variable, in some cases very high and in some very low. Because Q fever endocarditis is a chronic illness, a single serum specimen may be diagnostic and paired sera are not required. Furthermore, the antibody titers can be used to monitor the course of treatment. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Duke criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Duke criteria are generally used to establish the diagnosis of infective endocarditis (",
"    <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"UTD.htm?42/47/43773\">",
"     table 1A-B",
"    </a>",
"    ). These criteria are most accurate when applied to common organisms such as viridans streptococci, Staphylococcus aureus, and enterococci. One problem in Q fever is that transthoracic echocardiography is frequently inconclusive; transesophageal echocardiography is superior but often fails to show vegetations although valvular dysfunction can be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of Duke criteria in Q fever endocarditis was evaluated in a series of 20 cases proven by pathologic examination of the valve; four were misclassified as \"possible\" using the initial standard criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/16\">",
"     16",
"    </a>",
"    ]. However, all were correctly classified if a single positive blood culture for Coxiella burnetii and an antiphase I IgG antibody titer &gt;800 were changed from minor to major criteria. For this reason, modifications of the Duke criteria have been made for the diagnosis of Q fever endocarditis, making Q fever serology a major criterion (",
"    <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"UTD.htm?42/47/43773\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of C. burnetii by DNA amplification using the polymerase chain reaction has been described. This technique can be applied to culture supernatants and various tissue samples (particularly valve samples) and has the advantage of needing no viable microorganisms (frozen, formalized, or paraffin-embedded tissue sections).",
"   </p>",
"   <p>",
"    The development of a rapid nested-PCR assay using serum as a template and the LightCycler as a thermal cycler may enable early diagnosis of acute Q fever endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/18\">",
"     18",
"    </a>",
"    ]. The performance of this assay was evaluated in a series of 191 patients (48 with Q fever endocarditis or vascular infection, 100 with endocarditis caused by other microorganisms, 30 with treated Q fever endocarditis, and 13 with possible Q fever endocarditis but ambiguous IgG phase I titers) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/18\">",
"     18",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specificity was 100 percent for untreated Q fever endocarditis; all samples from patients with treated Q fever endocarditis and convalescent acute (late) Q fever were negative.",
"     </li>",
"     <li>",
"      The sensitivity was 64 to 100 percent for acute Q fever endocarditis.",
"     </li>",
"     <li>",
"      The sensitivity was decreased if sera was stored at -20&ordm;C for more than one month compared to fresh sera, and in sera with IgG phase I titers of &ge;25,600 presumably due to inhibition of the PCR by IgG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using immunohistochemical analysis, culture, and PCR of valve tissue in a series of 28 patients with Q fever endocarditis, one group was able to identify C. burnetii for one year after antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/19\">",
"     19",
"    </a>",
"    ]. The histopathology of the valves in this series demonstrated significant fibrosis and calcification but not inflammation or large vegetations. Thus, specific testing for C. burnetii was required to distinguish this from non-infectious endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods of diagnosis of Q fever endocarditis include the isolation or demonstration of C. burnetii in the tissues (heart valves, liver biopsies, embolic material) using special stains, immunofluorescence with specific polyclonal or monoclonal antibodies, or electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. burnetii can also be isolated using animal inoculation or cultivated in embryonated eggs or cell culture. The last technique is performed on human fibroblasts grown in shell vials, using immunofluorescence to detect the antigens after an incubation time of only six days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/22\">",
"     22",
"    </a>",
"    ]. Cell culture is easier and less hazardous than animal inoculation but is only available in specially equipped laboratories. Blood buffy coat, valves, and biopsies can be used for isolation of the bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prevention or early diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The suggestion that early diagnosis may minimize the clinical manifestations of Q fever endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/9\">",
"     9",
"    </a>",
"    ] and the observation that the mortality rate may be as high as 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2\">",
"     2",
"    </a>",
"    ] has led to the proposal of a serologic follow-up strategy in patients with acute Q fever to prevent endocarditis in patients with valve disease and to permit early detection in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach has the following components and is applied to all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of Q fever is established, transthoracic echocardiography is performed. If valve lesions are detected, the patient is treated for one year using the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      regimen described below in an attempt to prevent endocarditis, since these patients are at high risk for endocarditis (39 percent in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/3\">",
"       3",
"      </a>",
"      ]) and there is observational evidence that the combined regimen reduces the incidence of endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If transthoracic echocardiography does not detect valve lesions, serologic testing is performed at three and six months:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the anti-phase I IgG titer is &lt;800 at both times, no further evaluation is performed.",
"     </li>",
"     <li>",
"      If the anti-phase I IgG titer is &ge;800 on either measurement, perform transesophageal echocardiography, which is more sensitive than transthoracic echocardiography for the diagnosis of endocarditis, and polymerase chain reaction on serum samples to detect C. burnetii. If either test is positive, the patient is treated for Q fever endocarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Other methods'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite seemingly adequate medical therapy of Q fever endocarditis, relapses and positive valve cultures have been observed several years later, even in patients who undergo surgery for the valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. There is at present no specific test that makes it possible to conclude that a patient has definitively been cured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotic regimen may be influenced by the antibiotic susceptibility of the isolate, if available. The necessity of antibiotic susceptibility is illustrated by a study that evaluated 16 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/24\">",
"     24",
"    </a>",
"    ]. A rapid clinical and serologic response was associated with a ratio of serum doxycycline concentration to MIC of &ge;1. The only patient who died from infection had a ratio of &lt;0.5; the C. burnetii isolate was resistant to doxycycline (MIC of 8",
"    <span class=\"nowrap\">",
"     microgram/mL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drug regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    is usually the mainstay of treatment of Q fever endocarditis. Prescribed alone, it seems to improve the medical condition of patients for as long as it is given. However, recovery of viable C. burnetii from valve tissue has been reported after four years of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . Since doxycycline alone does not cure Q fever endocarditis, combination antibiotic therapy has been proposed.",
"   </p>",
"   <p>",
"    The preferred regimen for the treatment of Q fever endocarditis is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . In vitro, 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    makes doxycycline bactericidal against intracellular organisms.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (600 mg daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200 mg daily) was suggested in a retrospective comparison to doxycycline plus a quinolone in a study 35 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the 21 patients treated with this regimen (all after May 1991), 17 were cured and no relapses were observed in patients treated for more than 18 months. In comparison, among the 14 patients treated with doxycycline and a quinolone before May 1991, only five were considered cured after a mean duration of 55 months of therapy.",
"   </p>",
"   <p>",
"    The serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    concentration should be monitored in order to obtain a concentration of 1&plusmn;0.2",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    retinal examinations should be performed every six months to detect early signs of ophthalmologic toxicity such as corneal deposits and retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    concentrations should be monitored and the level maintained at &ge;5",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    The rationale for this recommendation comes from a retrospective study of 24 patients with Q fever endocarditis treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (600 mg daily) and doxycycline (200 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with higher serum doxycycline concentrations (5.3 compared to 3.1",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    had a more rapid clinical response (as measured by a decrease in phase 1 antibody).",
"   </p>",
"   <p>",
"    Several alternative combination regimens have been evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (900",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      has been effective in some case reports. However, rifampin accelerates",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      metabolism and may make anticoagulation difficult. A higher warfarin dose is required to achieve effective anticoagulation and, if rifampin is discontinued, careful attention to excess bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A quinolone, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (1500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      may be more effective than doxycycline alone.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (cotrimoxazole) added to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      remains controversial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initiation of effective antibiotic therapy, the patient usually becomes afebrile within one week, and the hepatomegaly and splenomegaly disappear slowly within 2 to 12 weeks. Other parameters such as elevated serum aminotransferases and thrombocytopenia also slowly return to normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monitoring treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing should be performed during therapy. We usually obtain titers every month for one year, every three months for two years, and then every six months thereafter to detect possible relapse. The serum levels of antibodies decrease very slowly. IgM antibodies, when present, disappear first and then IgA; however, IgG antibodies remain positive for years. After three years, treatment can be stopped if the titer of IgG antibodies against phase I antigens is still below 400.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum duration of therapy is 18 months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. We do not prolong treatment after three years unless there is no decrease of IgG antibodies. Some recommend life-long therapy with doxycycline following the initial combination treatment. There is a major risk of sunburn, since tetracyclines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    are photosensitizing; as a result, sun protection should be employed in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Surgical valve replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery to replace a damaged valve in Q fever endocarditis is generally indicated for hemodynamic reasons. If possible, at least three weeks of antimicrobial treatment should be given prior to valve replacement. Although not curative, three weeks of therapy should sterilize the blood, minimizing the risk of infection of the new valve [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15255/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24975306\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of Q fever endocarditis in patients with Q fever primarily occurs in patients with previous valvular disease or immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Q fever endocarditis is a severe and often fatal disease. Many patients have previously known valvulopathy and present with symptoms of heart failure, valve dysfunction, or with constitutional symptoms, including fever, malaise, weakness, weight loss, fatigue, chills, anorexia, and night sweats. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings in Q fever endocarditis are largely nonspecific and include an elevated erythrocyte sedimentation rate, anemia, thrombocytopenia, and hematuria. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Q fever is confirmed by serologic testing for antibodies to phase I and phase II antigens. The most commonly used serologic technique is the microimmunofluorescence (MIF) test, which should distinguish between titers of IgG and IgM antibodies. A titer &ge;200 for IgG and &ge;50 for IgM against phase II indicates a recent Q fever infection, while an IgG titer &gt;800 against phase I suggests chronic infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred regimen for the treatment of Q fever endocarditis is the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (600 mg daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg daily). Surgery to replace a damaged valve in Q fever endocarditis is generally indicated for hemodynamic reasons. If possible, at least three weeks of antimicrobial treatment should be given prior to valve replacement. Although not curative, three weeks of therapy should sterilize the blood, minimizing the risk of infection of the new valve. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/1\">",
"      Raoult D, Marrie T. Q fever. Clin Infect Dis 1995; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/2\">",
"      Brouqui P, Dupont HT, Drancourt M, et al. Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. Arch Intern Med 1993; 153:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/3\">",
"      Fenollar F, Fournier PE, Carrieri MP, et al. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 2001; 33:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/4\">",
"      Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/5\">",
"      Fenollar F, Thuny F, Xeridat B, et al. Endocarditis after acute Q fever in patients with previously undiagnosed valvulopathies. Clin Infect Dis 2006; 42:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/6\">",
"      Landais C, Fenollar F, Thuny F, Raoult D. From acute Q fever to endocarditis: serological follow-up strategy. Clin Infect Dis 2007; 44:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/7\">",
"      Raoult D, Tissot-Dupont H, Foucault C, et al. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore) 2000; 79:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/8\">",
"      Stein A, Raoult D. Q fever endocarditis. Eur Heart J 1995; 16 Suppl B:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/9\">",
"      Raoult D, Etienne J, Massip P, et al. Q fever endocarditis in the south of France. J Infect Dis 1987; 155:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/10\">",
"      Houpikian P, Habib G, Mesana T, Raoult D. Changing clinical presentation of Q fever endocarditis. Clin Infect Dis 2002; 34:E28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/11\">",
"      Korman TM, Spelman DW, Perry GJ, Dowling JP. Acute glomerulonephritis associated with acute Q fever: case report and review of the renal complications of Coxiella burnetii infection. Clin Infect Dis 1998; 26:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/12\">",
"      Levy P, Raoult D, Razongles JJ. Q-fever and autoimmunity. Eur J Epidemiol 1989; 5:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/13\">",
"      Hoen B, Selton-Suty C, Lacassin F, et al. Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin Infect Dis 1995; 20:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/14\">",
"      Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005; 84:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/15\">",
"      Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol 1998; 36:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/16\">",
"      Fournier PE, Casalta JP, Habib G, et al. Modification of the diagnostic criteria proposed by the Duke Endocarditis Service to permit improved diagnosis of Q fever endocarditis. Am J Med 1996; 100:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/17\">",
"      Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/18\">",
"      Fenollar F, Fournier PE, Raoult D. Molecular detection of Coxiella burnetii in the sera of patients with Q fever endocarditis or vascular infection. J Clin Microbiol 2004; 42:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/19\">",
"      Lepidi H, Houpikian P, Liang Z, Raoult D. Cardiac valves in patients with Q fever endocarditis: microbiological, molecular, and histologic studies. J Infect Dis 2003; 187:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/20\">",
"      M&uuml;hlemann K, Matter L, Meyer B, Schopfer K. Isolation of Coxiella burnetii from heart valves of patients treated for Q fever endocarditis. J Clin Microbiol 1995; 33:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/21\">",
"      Brouqui P, Dumler JS, Raoult D. Immunohistologic demonstration of Coxiella burnetii in the valves of patients with Q fever endocarditis. Am J Med 1994; 97:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/22\">",
"      Musso D, Raoult D. Coxiella burnetii blood cultures from acute and chronic Q-fever patients. J Clin Microbiol 1995; 33:3129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/23\">",
"      Raoult D. Treatment of Q fever. Antimicrob Agents Chemother 1993; 37:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/24\">",
"      Rolain JM, Boulos A, Mallet MN, Raoult D. Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis. Antimicrob Agents Chemother 2005; 49:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/25\">",
"      Raoult D, Houpikian P, Tissot Dupont H, et al. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999; 159:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/26\">",
"      Rolain JM, Mallet MN, Raoult D. Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J Infect Dis 2003; 188:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15255/abstract/27\">",
"      O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975; 83:506.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2153 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15255=[""].join("\n");
var outline_f14_57_15255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24975306\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peripheral manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Q fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prevention or early diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drug regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monitoring treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Surgical valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24975306\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9644\" title=\"table 1A\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6653\" title=\"table 1B\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=related_link\">",
"      Microbiology and epidemiology of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5556?source=related_link\">",
"      Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15256="Techniques for neonatal circumcision";
var content_f14_57_15256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques for neonatal circumcision",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15256/contributors\">",
"     David G Weismiller, MD, ScM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15256/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/57/15256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision (Latin circumcido, to cut around) is an elective surgical procedure in which the prepuce or foreskin (skin covering the glans penis) is removed. The three major techniques for performing neonatal circumcision are use of the Gomco clamp, Hollister Plastibell, or Mogen clamp. These techniques will be reviewed here. A detailed discussion of the risks and benefits of neonatal circumcision can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link\">",
"     \"Neonatal circumcision: Risks and benefits\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL DEVELOPMENT AND ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penis consists of a proximal root, middle body (corpus or shaft), and distal head (glans). The prominent circumferential rim where the glans begins is called the glans corona, and the constriction just below the corona is the coronal sulcus (",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin of the body of the penis starts to grow over the glans between 10 and 18 weeks of gestation, eventually covering the entire organ [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/1\">",
"     1",
"    </a>",
"    ]. The prepuce is a specialized, junctional mucocutaneous tissue that forms the transition between the mucosal epithelium of the glans and the keratinized epithelium of the penile shaft, analogous to the eyelids. The double sheet of prepuce covers the glans for a variable distance and consists of several thin layers: inner squamous epithelium (mucosa), lamina propria, dartos muscle, dermis, and outer keratinized stratified squamous epithelium (",
"    <a class=\"graphic graphic_figure graphicRef86376 \" href=\"UTD.htm?30/2/30752\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/2\">",
"     2",
"    </a>",
"    ]. The frenulum is a ridge of tissue that extends from the base of the prepuce at the coronal sulcus to a point just inferior to the external urethral orifice (meatus) (",
"    <a class=\"graphic graphic_figure graphicRef86377 \" href=\"UTD.htm?39/29/40414\">",
"     figure 3",
"    </a>",
"    ). It is supplied by the frenular artery and vein, which can cause significant bleeding if disrupted during circumcision.",
"   </p>",
"   <p>",
"    At birth, the prepuce is fused to the glans by filmy adhesions that prevent retraction (congenital or physiological phimosis). These adhesions resolve over time due to desquamation and epidermal keratinization. The resulting separation of the prepuce and the glans is called the preputial space and allows easy retraction.",
"   </p>",
"   <p>",
"    Separation is completed in 50 percent of boys by age 3 years, 95 percent by age 5 years, and 99 percent by adolescence. In a small number of uncircumcised males, partial adhesions leading to accumulation of smegma may persist throughout childhood, and even into adolescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667380\">",
"    <span class=\"h2\">",
"     After circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision removes some sensory receptors and most of the dartos muscle. The exposed glans mucosa becomes keratinized. The urethral meatus becomes more prone to external irritation due to exposure and, if the frenular artery is ablated, the blood supply may be reduced; these changes can lead to meatal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING OF CIRCUMCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the optimal time for performing circumcision. The procedure is generally performed on healthy, medically stable, term infants between one and eight days after birth. A minimum period of 24 hours of observation after delivery provides time to detect abnormalities or illnesses that might need to be addressed before the elective procedure is performed (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Contraindications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Most circumcisions are performed in the hospital before the infant (term or preterm) is discharged as this is convenient for parents, practical, and has a demonstrated record of safety. In some areas, the procedure on term infants is performed after discharge to assure that the infant is medically stable (eg, no longer losing weight, tolerating feeding, voiding, stooling, and jaundice has resolved or is waning). The safety of delayed circumcision is supported by data from ritual circumcisions in Judaism, which must be performed on the eighth day from the baby's birth. It is also supported by a prospective cohort study that compared 250 early (age 1 to 4 days) circumcisions with 100 late (age 5 months) circumcisions performed under local anesthesia by a single pediatric surgeon using a bone cutter (similar to a Mogan clamp), Gomco clamp, or Plastibell for early procedures and Plastibell for late procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/3\">",
"     3",
"    </a>",
"    ]. In this study, late procedures appeared to be associated with fewer complications and a more satisfactory cosmetic appearance than early procedures. Infant comfort and relative costs were not evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major contraindications to neonatal circumcision are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding diathesis",
"     </li>",
"     <li>",
"      Congenital penile anomalies",
"     </li>",
"     <li>",
"      Medical instability. This includes term newborns who are ill, as well as low",
"      <span class=\"nowrap\">",
"       birthweight/premature",
"      </span>",
"      infants who are not ready for discharge from the nursery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of significant bleeding is increased if there is an underlying coagulopathy; therefore, a family history of bleeding diathesis or evidence of neonatal petechiae or neonatal bleeding diathesis should prompt hematological evaluation prior to the procedure. A neonatal platelet count should be obtained in asymptomatic neonates who are at high risk of thrombocytopenia. Consultation with a pediatric hematologist before the procedure is advised when there is suspicion of a bleeding diathesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The penis should be examined carefully for congenital anomalies before circumcision, as some anatomic abnormalities (eg, congenital chordee, penoscrotal fusion, congenital buried penis, urethral abnormalities) increase the risk of an adverse outcome. If an anomaly is identified, consultation with a urologist should be obtained prior to the procedure to determine whether the procedure should be performed, timing, and the appropriate surgeon.",
"   </p>",
"   <p>",
"    Hypospadias has been considered a contraindication to circumcision because foreskin removal could complicate future urethroplasty. If the procedure is started and a dorsal slit (see below) is made before the anomaly is detected, most experts recommend that the procedure be stopped and the slit suture repaired. However, observational studies of the subgroup of hypospadias patients with an intact prepuce report urethroplasty can be accomplished after circumcision without use of skin flaps by using urethral plate tubularization and coverage of the neourethra by a dartos flap [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Nevertheless, we suggest avoiding circumcision in infants with all degrees of hypospadias so as to give the urologic surgeon more options during repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"     \"Hypospadias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newborns with a small penis, buried or concealed penis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    especially large suprapubic fat pad should have circumcision delayed until the abnormal anatomy resolves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PARENTS' FINANCIAL OBLIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under some insurance plans, circumcision is not a covered benefit. Parents should be aware that they may be responsible for the cost of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should confirm the following prior to performing the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The infant is at least 12 hours old (preferably 24 hours old)",
"     </li>",
"     <li>",
"      The infant has voided at least once since birth",
"     </li>",
"     <li>",
"      The infant has not eaten for at least one hour prior to circumcision",
"     </li>",
"     <li>",
"      Written parental consent has been obtained",
"     </li>",
"     <li>",
"      The correct infant has been brought to the procedure room",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) also recommends confirmation that the infant has received standard vitamin K prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/6\">",
"     6",
"    </a>",
"    ]. Vitamin K deficiency bleeding in the first few days of life is rare, but a potential and preventable risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks and benefits of circumcision should be thoroughly reviewed with parents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=see_link&amp;anchor=H5#H5\">",
"     \"Neonatal circumcision: Risks and benefits\", section on 'Counseling'",
"    </a>",
"    .) In addition to this discussion, we provide written information to all parents of male infants; the document we provide to our patients is shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef65954 graphicRef74975 \" href=\"UTD.htm?24/19/24893\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infancy is the optimal time for circumcision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/9\">",
"     9",
"    </a>",
"    ]. There is some debate regarding whether parents have a legal right to give informed permission for the procedure rather than delaying it until the child reaches the age of assent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/10\">",
"     10",
"    </a>",
"    ]. The judicial system has allowed parents to make this decision in the best interest of their child. However, there have been cases where adult men have brought legal action against their parents and the operating physician because of lack of consent; only one such case has been successful (ended in a settlement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PAIN CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with major guidelines that recommend pharmacologic analgesia for safe and effective pain control during circumcision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Newborns undergoing circumcision without analgesia exhibit behavioral and physiological signs of stress, such as crying and increased heart rate and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/13\">",
"     13",
"    </a>",
"    ]. The stress may be due, in part, to the fact that infants are restrained prior to circumcision and almost all newborns dislike being restrained. Pain is also a factor as physiological sequelae of pain are observed during the most painful parts of the procedure. Interestingly, in 1860 when circumcision began to gain in popularity in the English speaking world, pain during circumcision was desirable. An article in Lancet stated, \"the operation, too, should not be performed under chloroform, so that the pain experienced may be associated with the habit [masturbation] we wish to eradicate\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical anesthetics (eg, 4 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    cream; EMLA cream: 2.5 percent lidocaine and 2.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    ) are easy to administer and have been proven to reduce pain during circumcision compared to no anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/15\">",
"     15",
"    </a>",
"    ], but in a randomized trial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32150?source=see_link\">",
"     lidocaine-prilocaine",
"    </a>",
"    was not as effective as a nerve block [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dorsal penile nerve block or circumferential subcutaneous local anesthesia (ring block) offer the best pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Ring block appears to be more effective than dorsal penile nerve block, but data are limited to one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/16\">",
"     16",
"    </a>",
"    ]. We prefer 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    <strong>",
"     without",
"    </strong>",
"    epinephrine, and we avoid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    because of its increased potential for cardiovascular toxicity.",
"   </p>",
"   <p>",
"    Irrespective of the technique used, it is important to wait long enough to allow the anesthetic to take effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical anesthesia",
"      </strong>",
"      &mdash; Topical 4 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32150?source=see_link\">",
"       lidocaine-prilocaine",
"      </a>",
"      cream are similarly effective for circumcision [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], but 4 percent lidocaine is preferred because of faster onset on action (20 to 30 minutes versus 60 to 90 minutes) and fewer side effects and adverse reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/12\">",
"       12",
"      </a>",
"      ]. Newborns may be predisposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      -related methemoglobinemia because they have low levels of methemoglobin reductase. In addition, topical anesthetics have been associated with an increased risk of skin irritation (erythema, swelling, blistering) in low birthweight infants; the risk is higher with topical lidocaine-prilocaine cream than with 4 percent lidocaine.",
"      <br/>",
"      <br/>",
"      For term neonates, two grams of the topical cream are applied to the foreskin and penis, which is wrapped with an occlusive dressing until the anesthetic takes effect. The use of topical anesthetics is described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dorsal penile nerve block",
"      </strong>",
"      &mdash; A 27 or 30 gauge needle attached to a 1 mL syringe is inserted at the 2 o'clock position at the base of the penis in a posteromedial direction and to a depth of 0.3 to 0.5 cm beneath the skin surface [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/20\">",
"       20",
"      </a>",
"      ]. The tip of the needle should be freely movable, indicating that it is imbedded in loose connective tissue. Once the needle is properly placed and negative pressure reveals no blood, 0.4 mL of 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      <strong>",
"       without",
"      </strong>",
"      epinephrine is injected. The needle is then withdrawn and the procedure repeated at 10 o'clock (",
"      <a class=\"graphic graphic_figure graphicRef68040 \" href=\"UTD.htm?33/29/34258\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71880 \" href=\"UTD.htm?27/63/28671\">",
"       picture 1",
"      </a>",
"      ). The anesthetic takes effect in about seven minutes.",
"     </li>",
"     <li>",
"      <strong>",
"       Ring block",
"      </strong>",
"      &mdash; A 27 or 30 gauge needle attached to a 1 mL syringe is inserted into the lateral side of the penis at the base and 0.4 mL of 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      <strong>",
"       without",
"      </strong>",
"      epinephrine is injected subcutaneously to create a bleb [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/20\">",
"       20",
"      </a>",
"      ]. The needle is then advanced circumferentially around the base of the penis, completing a 180 degree half circle. Intravascular injection can be avoided by frequently applying negative pressure prior to enlarging the subcutaneous ring. The procedure is repeated on the opposite side of the penis, so that a circumferential ring of anesthesia is completed around the penis. The anesthetic takes effect in about seven minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common complications of dorsal penile nerve blocks and ring blocks are bruising, bleeding, and inadequate analgesia; hematomas occur rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/21\">",
"     21",
"    </a>",
"    ]. Toxicity from systemic absorption as a result of injection into a blood vessel can be avoided by aspirating to check for blood before injecting and, for the dorsal block, by injecting at the 10 and 2 o'clock positions, rather than in the midline.",
"   </p>",
"   <p>",
"    Giving the infant a sucrose-dipped pacifier (24 percent solution) during",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after the procedure appears to provide additional comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/22\">",
"     22",
"    </a>",
"    ], but is not a substitute for topical anesthesia or nerve block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision should only be performed by well-trained practitioners, who may or may not be clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/12,23,24\">",
"     12,23,24",
"    </a>",
"    ]. These individuals should be proficient in assessment of the infant for circumcision, administration of anesthesia, sterile procedural technique, and evaluation and management or referral of potential complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Instrumentation and materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The room should have adequate warmth and lighting. The infant is typically placed on a circumcision board (eg, Circumstraint&reg;), which restricts his movement during the procedure.",
"   </p>",
"   <p>",
"    Ideally, a complete set of circumcision instruments in the full range of available sizes should be accessible. The clinician should ensure that all instruments are present, sterile, come together with precision, and have no defects. Anesthetic agents, a 1 mL syringe attached to a 27 to 30 gauge needle, alcohol pads, and antiseptic swabs or solution should be within easy reach. A 3-mL syringe with an 18 to 22 gauge needle is also needed for drawing up anesthetic.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/4/18499?source=see_link\">",
"     Absorbable gelatin sponge",
"    </a>",
"    (eg, Gelfoam&reg;),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    sticks, and fine absorbable sutures should be available to control bleeding, if necessary.",
"   </p>",
"   <p>",
"    The Centers for Disease Control (CDC) published a report on 11 cases of neonatal methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infection in a well-infant nursery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/25\">",
"     25",
"    </a>",
"    ]. Uncovered circumcision equipment, use of multiple-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    vials, and inadequate hand hygiene practices were associated with these infections, and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant is placed in a suitable restraint (",
"    <a class=\"graphic graphic_picture graphicRef52873 \" href=\"UTD.htm?10/16/10497\">",
"     picture 2",
"    </a>",
"    ); physiologic positioning and use of a padded restraint appear to improve infant comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/12\">",
"     12",
"    </a>",
"    ]. The penis and at least a one-inch area of skin around the base of the penis are thoroughly scrubbed with at least three applications of an antiseptic agent (eg, chlorhexidine-alcohol) (",
"    <a class=\"graphic graphic_picture graphicRef65808 \" href=\"UTD.htm?24/31/25087\">",
"     picture 3",
"    </a>",
"    ). Excess antiseptic is wiped off with sterile gauze and a sterile fenestrated drape is placed to expose the penis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wound infection (0.06 percent) and bacteremia (0.008 percent) are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/26\">",
"     26",
"    </a>",
"    ]; therefore, neither antibiotic prophylaxis nor endocarditis prophylaxis (for infants with congenital heart disease) is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major techniques for circumcision are use of the Gomco clamp, Plastibell device, or Mogen clamp. Choice of modality depends upon clinician preference. The device that leads to the best results with the fewest complications is unclear as no randomized trials have directly compared these techniques. Procedures using the Mogen clamp take less time and thus may cause less distress than the Gomco clamp or Plastibell device, but require more expertise to achieve an optimal result. &nbsp;",
"   </p>",
"   <p>",
"    Procedural principles common to all three techniques include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appropriate amount of foreskin to be removed needs to determined.",
"     </li>",
"     <li>",
"      The preputial orifice needs to be dilated so the glans can be examined for congenital anomalies.",
"     </li>",
"     <li>",
"      Adhesions that are normally present between the inner preputial epithelium and the epithelium of the glans need to be lysed.",
"     </li>",
"     <li>",
"      The circumcision clamp needs to be in place long enough to produce hemostasis.",
"     </li>",
"     <li>",
"      The prepuce is removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important step in all circumcision procedures is insuring that the prepuce is not pulled too tightly or too loosely before it is excised; otherwise, too much or too little skin will be removed. We suggest marking the location of the corona with a pen or by placement of a hemostat to help guide this decision.",
"   </p>",
"   <p>",
"    <strong>",
"     The most important step is to ensure that the inner preputial epithelium is completely free from the glans and that the entire coronal sulcus is visualized before excision is performed.",
"    </strong>",
"    Care must be taken to avoid vigorously disrupting the ventral frenulum and the vessels in the frenulum, as excessive trauma can lead to increased bleeding.",
"   </p>",
"   <p>",
"    Most bleeding can be controlled with simple pressure on the area; ligation with a fine suture is required occasionally. If a hemostatic stitch placed in the frenulum enters the urethra, which is in close proximity, a urinary fistula can result. Therefore, it is important to ensure only superficial tissue is included in any stitches placed for hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gomco clamp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gomco clamp is a three-part device (base plate, bell, lock) (",
"    <a class=\"graphic graphic_picture graphicRef76052 \" href=\"UTD.htm?38/31/39409\">",
"     picture 4",
"    </a>",
"    ). The clamp crushes about 1 mm of the foreskin circumferentially, while the bell protects the head of the penis from injury by separating the glans from the inner preputial mucosa during removal of the foreskin. Bells for circumcision of the newborn typically come in three sizes; the appropriate size is estimated based upon the circumference of the glans. For a correct fit, the edge of the bell should reach the frenulum and minimally extend over the corona, slightly stretching the preputial skin.",
"   </p>",
"   <p>",
"    Procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply two hemostats at the 3 and 9 o'clock positions on the foreskin (",
"      <a class=\"graphic graphic_picture graphicRef76494 \" href=\"UTD.htm?5/45/5840\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      While maintaining traction with the attached hemostats, open the third hemostat and sweep around the glans to break adhesions between the glans and inner mucosal layer of the foreskin, being careful to avoid the 5 to 7 o'clock position at the frenulum, which contains an arteriole (",
"      <a class=\"graphic graphic_picture graphicRef59130 \" href=\"UTD.htm?40/6/41071\">",
"       picture 6",
"      </a>",
"      ). Also be careful to clearly visualize the tip of the hemostat to make sure it does not go beyond the coronal sulcus or enter the meatus. If the mucosal adhesions are not completely separated from the coronal sulcus, then not enough mucosa will be removed with the foreskin and the glans will not be completely exposed after the procedure.",
"     </li>",
"     <li>",
"      Remove the third hemostat and use it to clamp the foreskin at the 12 o'clock position so that the hemostat tip is 0.5 cm from the coronal sulcus. The skin should be relaxed and fairly supple. If it is too taut, too much foreskin may be removed. Remove this hemostat and use scissors to cut along the crushed skin to its most proximal point (",
"      <a class=\"graphic graphic_picture graphicRef53911 \" href=\"UTD.htm?9/2/9248\">",
"       picture 7",
"      </a>",
"      ). Crushing the tissue before cutting minimizes bleeding.",
"     </li>",
"     <li>",
"      Retract the foreskin and remove any remaining adhesions with blunt dissection using gauze or a probe. The entire coronal sulcus should be visible.",
"     </li>",
"     <li>",
"      Replace the foreskin over the glans.",
"     </li>",
"     <li>",
"      Place the bell inside the foreskin and over the glans (",
"      <a class=\"graphic graphic_picture graphicRef67747 \" href=\"UTD.htm?36/27/37311\">",
"       picture 8",
"      </a>",
"      ) and remove the two hemostats. It is important to ensure that the apex of the crush",
"      <span class=\"nowrap\">",
"       injury/incision",
"      </span>",
"      is visible above the rim of the bell to prevent notching at the border of the foreskin during removal.",
"     </li>",
"     <li>",
"      Slip the handle of the bell through the circular opening of the base plate, without letting the foreskin slip off. The foreskin with its underlying mucosa can be held in place while being advanced through the opening by grasping them with forceps, hemostats, or a sterile safety pin (",
"      <a class=\"graphic graphic_picture graphicRef69386 graphicRef77024 graphicRef77467 \" href=\"UTD.htm?10/9/10392\">",
"       picture 9A-C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Inspect to ensure that equal amounts of foreskin and mucosa are present circumferentially and judge the amount of the shaft skin left below the corona; this skin should be relaxed and supple. If it is taut, too much foreskin may be removed. The amount of foreskin above the base plate can be adjusted at this time so the appropriate amount will be excised; however, this requires removing the bell from the yoke and then readjusting the bell, foreskin, and underlying mucosa.",
"     </li>",
"     <li>",
"      It is essential to check that the crossbar at the top of the bell sits squarely in the yoke of the clamp so pressure will be evenly distributed around the bell. Tighten the thumbscrew until snug to crush the foreskin between the bell and base plate; then cut the foreskin at the base plate using a scalpel blade. Electrocautery devices should",
"      <strong>",
"       never",
"      </strong>",
"      be used to excise foreskin because of the risk of thermal injury from conduction by the metal clamp.",
"     </li>",
"     <li>",
"      Carefully remove any remaining tissue in and around the groove that connects the clamp and bell.",
"     </li>",
"     <li>",
"      The clamp is secured for a total duration of at least three, and preferably five,",
"      <strong>",
"      </strong>",
"      minutes to allow optimal time for hemostasis from compression. After five minutes, loosen the thumbscrew and gently remove the clamp and bell (",
"      <a class=\"graphic graphic_picture graphicRef56564 \" href=\"UTD.htm?25/61/26591\">",
"       picture 10",
"      </a>",
"      ). Tissue edema can lead to oozing from the crushed edge, so care should be taken to minimize excessive trauma of the foreskin during and after the procedure.",
"     </li>",
"     <li>",
"      Push any remaining shaft skin below the corona with gauze. However, if the majority of the glans is not exposed following circumcision, too little skin was removed and the patient may need to be referred to a pediatric urologist; the Gomco procedure should not be repeated. Conversely, if the shaft below the corona is not covered with skin after the circumcision, too much skin was probably removed and the patient may need to be referred to a pediatric urologist.",
"     </li>",
"     <li>",
"      Inspect the penis for bleeding, especially in the area of the frenulum (",
"      <a class=\"graphic graphic_picture graphicRef53175 \" href=\"UTD.htm?14/53/15199\">",
"       picture 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Place a small nonstick bandage or petroleum gauze around the cut edge of the foreskin and then wrap the penis with a dressing, which should remain in place for 12 to 24 hours (",
"      <a class=\"graphic graphic_picture graphicRef73579 graphicRef50531 \" href=\"UTD.htm?2/5/2135\">",
"       picture 12A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plastibell device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Plastibell device is a plastic bell with a groove around the edge. It is placed under the foreskin and over the glans, after which a suture is tied in the groove. The suture cuts off the blood supply to the foreskin, which ultimately drops off along with the bell.",
"   </p>",
"   <p>",
"    The procedure begins in the same way as that for the Gomco clamp, described above ((see",
"    <a class=\"local\" href=\"#H13\">",
"     'Gomco clamp'",
"    </a>",
"    above), first five bullets), except the dorsal slit incision should be just long enough to accommodate the Plastibell device (",
"    <a class=\"graphic graphic_figure graphicRef63926 \" href=\"UTD.htm?5/41/5777\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Select the Plastibell cap that best fits the glans (six sizes are available). A cap that is too small will not allow sufficient foreskin to be removed, and a cap that is too large will cause the removal of excess foreskin. The proper fit is a cap that fits halfway down the glans. The groove is always distal to the corona.",
"     </li>",
"     <li>",
"      Separate the two sides of the dorsal slit incision to expose the glans, put the Plastibell device over the glans, and then close the foreskin over it. The foreskin must not be pulled too tightly, as excessive tension could pull the device back onto the shaft and compress the urethra.",
"     </li>",
"     <li>",
"      Wrap the string securely around the foreskin in the groove at the base of the bell. Some devices have a handle that helps secure the device and must be snapped off once the device has been secured.",
"     </li>",
"     <li>",
"      The excess foreskin above the suture can be removed so there is less necrotic tissue present.",
"     </li>",
"     <li>",
"      Discharge the infant with the bell part of the device still attached. The remaining foreskin, having lost its blood supply, will fall off with the bell in 6 to 12 days, completing the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the device does not fall off during this interval, the parents should notify the physician promptly. Sometimes edema will trap the plastic ring on the penis, making it necessary to cut the ring off using a guide and ring cutter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15256/abstract/27\">",
"     27",
"    </a>",
"    ]. Venous congestion and necrosis can occur if the ring slips from the glans onto the penile shaft; this is a serious complication which can result in urinary tract obstruction, infection, and loss of penile tissue.",
"   </p>",
"   <p>",
"    Advantages of this technique are that the frenulum cannot be cut inadvertently and there are no incised edges that can bleed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mogen clamp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mogen clamp (",
"    <a class=\"graphic graphic_picture graphicRef74976 \" href=\"UTD.htm?22/3/22591\">",
"     picture 13",
"    </a>",
"    ) technique is the quickest, and therefore least painful, of the three procedures. Its disadvantage is that the glans is not well protected during clamping and cutting and thus may be injured. However, since the clamp only opens 3 mm, the chance of trapping the glans is minimal. The procedure begins in the same way as that for the Gomco clamp, described above ((see",
"    <a class=\"local\" href=\"#H13\">",
"     'Gomco clamp'",
"    </a>",
"    above), first five bullets).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place a hemostat in the dorsal midline with its tip about 3 mm short of the corona.",
"     </li>",
"     <li>",
"      Use your thumb and first finger of the nondominant hand to firmly grasp the foreskin below the tip of the hemostat and push the tip of the glans out of the way.",
"     </li>",
"     <li>",
"      Slide the Mogen clamp anteriorly to posteriorly just above your fingers to protect the glans when the clamp is applied. The clamp is placed at the same angle as the corona with the hollow side facing the glans. At this angle, more foreskin is removed dorsally than ventrally.",
"     </li>",
"     <li>",
"      Before locking the Mogen clamp shut, manipulate the glans to be sure it is free of the clamp.",
"     </li>",
"     <li>",
"      Close and lock the clamp (",
"      <a class=\"graphic graphic_picture graphicRef55011 \" href=\"UTD.htm?30/28/31183\">",
"       picture 14",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Remove the foreskin distal to the clamp with a scalpel blade (",
"      <a class=\"graphic graphic_picture graphicRef70782 \" href=\"UTD.htm?8/26/8608\">",
"       picture 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Leave the clamp on for a few moments to ensure hemostasis, then unlock and remove it. Hemostasis is dependent on the adequacy of the crush injury and absence of tissue edema, which can stress the cut edge.",
"     </li>",
"     <li>",
"      Retract the foreskin, which will be agglutinated by the clamp, and apply dressings as after the Gomco procedure (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Gomco clamp'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with the Gomco procedure, a small nonstick bandage or petroleum gauze is placed beneath a dressing and is removed the following day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications and their treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4903?source=see_link\">",
"     \"Complications of circumcision\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTCIRCUMCISION CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be provided with printed patient information about post-circumcision care. They should be informed that some swelling can be expected, that a crust will form on the area, and that some blood may be seen on the diaper, but the physician should be called if the blood stain is greater than the size of a quarter. The infant should urinate within 12 hours of the procedure.",
"   </p>",
"   <p>",
"    Petroleum ointment or a water based lubricant (eg, K-Y&reg; jelly) is placed over the wound for at least three to five days to prevent adhesion of the exposed glans to the diaper. The penis can be gently cleansed with soap and water if it is soiled. Otherwise, the entire penis is washed whenever the infant is bathed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=see_link\">",
"       \"Patient information: Circumcision in baby boys (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circumcision can be performed on healthy infants who are at least 24 hours old. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Timing of circumcision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major contraindications to neonatal circumcision are bleeding disorders, some penile anomalies, and medical instability. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend providing anesthesia during circumcision (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest using a local nerve block rather than a topical anesthetic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of any of the three major techniques for neonatal circumcision: Gomco clamp, the Plastibell device, or Mogen clamp (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important step when performing circumcision is to ensure that the inner preputial epithelium is completely free from the glans and that the entire coronal sulcus is visualized before excision is performed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is also important in all circumcision procedures to ensure that the foreskin is not pulled too tightly or too loosely before it is excised, otherwise too much or too little skin will be removed. We suggest marking the location of the corona with a pen or otherwise indicating its location by placement of hemostat to help guide this decision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/1\">",
"      Baskin LS. Fetal genital anatomy reconstructive implications. J Urol 1999; 162:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/2\">",
"      Cold CJ, Taylor JR. The prepuce. BJU Int 1999; 83 Suppl 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/3\">",
"      Machmouchi M, Alkhotani A. Is neonatal circumcision judicious? Eur J Pediatr Surg 2007; 17:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/4\">",
"      Snodgrass WT, Khavari R. Prior circumcision does not complicate repair of hypospadias with an intact prepuce. J Urol 2006; 176:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/5\">",
"      Pieretti RV, Pieretti A, Pieretti-Vanmarcke R. Circumcised hypospadias. Pediatr Surg Int 2009; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/6\">",
"      American Academy of Pediatrics Task Force on Circumcision. Circumcision policy statement. Pediatrics 2012; 130:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/7\">",
"      Darlow BA, Phillips AA, Dickson NP. New Zealand surveillance of neonatal vitamin K deficiency bleeding (VKDB): 1998-2008. J Paediatr Child Health 2011; 47:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/8\">",
"      Ipema HJ. Use of oral vitamin K for prevention of late vitamin k deficiency bleeding in neonates when injectable vitamin K is not available. Ann Pharmacother 2012; 46:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/9\">",
"      Morris BJ, Waskett JH, Banerjee J, et al. A 'snip' in time: what is the best age to circumcise? BMC Pediatr 2012; 12:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/10\">",
"      Van Howe RS, Svoboda JS, Dwyer JG, Price CP. Involuntary circumcision: the legal issues. BJU Int 1999; 83 Suppl 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/11\">",
"      American College of Obstetricians and Gynecologists. Committee on Obstetric Practice. ACOG Committee Opinion. Circumcision. Number 260, October 2001. Obstet Gynecol 2001; 98:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/12\">",
"      Blank S, Brady M, Buerk E, et al. Male circumcision. Pediatrics 2012; 130:e756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/13\">",
"      Taddio A, Stevens B, Craig K, et al. Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision. N Engl J Med 1997; 336:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/14\">",
"      Johnson, A. On an injurious habit occasionally met with in infancy and early childhood. Lancet 1860; 1:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/15\">",
"      Taddio A, Ohlsson K, Ohlsson A. Lidocaine-prilocaine cream for analgesia during circumcision in newborn boys. Cochrane Database Syst Rev 2000; :CD000496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/16\">",
"      Lander J, Brady-Fryer B, Metcalfe JB, et al. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. JAMA 1997; 278:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/17\">",
"      Brady-Fryer B, Wiebe N, Lander JA. Pain relief for neonatal circumcision. Cochrane Database Syst Rev 2004; :CD004217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/18\">",
"      Woodman PJ. Topical lidocaine-prilocaine versus lidocaine for neonatal circumcision: a randomized controlled trial. Obstet Gynecol 1999; 93:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/19\">",
"      Lehr VT, Cepeda E, Frattarelli DA, et al. Lidocaine 4% cream compared with lidocaine 2.5% and prilocaine 2.5% or dorsal penile block for circumcision. Am J Perinatol 2005; 22:231.",
"     </a>",
"    </li>",
"    <li>",
"     Mattson, SR. Routine anesthesia for circumcision. Postgrad Med 1999; 106: online edition. www.postgradmed.com/issues/1999/07_99/mattson.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/21\">",
"      Snellman LW, Stang HJ. Prospective evaluation of complications of dorsal penile nerve block for neonatal circumcision. Pediatrics 1995; 95:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/22\">",
"      Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2004; :CD001069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/23\">",
"      Ben Chaim J, Livne PM, Binyamini J, et al. Complications of circumcision in Israel: a one year multicenter survey. Isr Med Assoc J 2005; 7:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/24\">",
"      Ford N, Chu K, Mills EJ. Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis. AIDS 2012; 26:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/25\">",
"      Nguyen DM, Bancroft E, Mascola L, et al. Risk factors for neonatal methicillin-resistant Staphylococcus aureus infection in a well-infant nursery. Infect Control Hosp Epidemiol 2007; 28:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/26\">",
"      Wiswell TE, Geschke DW. Risks from circumcision during the first month of life compared with those for uncircumcised boys. Pediatrics 1989; 83:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15256/abstract/27\">",
"      al-Samarrai AY, Mofti AB, Crankson SJ, et al. A review of a Plastibell device in neonatal circumcision in 2,000 instances. Surg Gynecol Obstet 1988; 167:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5401 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15256=[""].join("\n");
var outline_f14_57_15256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL DEVELOPMENT AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H667380\">",
"      After circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING OF CIRCUMCISION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PARENTS' FINANCIAL OBLIGATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PAIN CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Instrumentation and materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gomco clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plastibell device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mogen clamp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTCIRCUMCISION CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5401|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19462\" title=\"figure 1\">",
"      Penis anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/2/30752\" title=\"figure 2\">",
"      Diagram of prepuce",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/29/40414\" title=\"figure 3\">",
"      Diagram of circumcised penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34258\" title=\"figure 4\">",
"      Dorsal penile nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/41/5777\" title=\"figure 5\">",
"      Plastibell procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5401|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/63/28671\" title=\"picture 1\">",
"      Dorsal penile nerve block2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/16/10497\" title=\"picture 2\">",
"      Restraint for circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/31/25087\" title=\"picture 3\">",
"      Penis being prepped",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/31/39409\" title=\"picture 4\">",
"      Disassembled Gomco clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/45/5840\" title=\"picture 5\">",
"      Hemostats applied to foreskin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/6/41071\" title=\"picture 6\">",
"      Breaking adhesions circumcision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/2/9248\" title=\"picture 7\">",
"      Cutting slit in foreskin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/27/37311\" title=\"picture 8\">",
"      Gomco bell applied to glans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/54/39776\" title=\"picture 9A\">",
"      Apply pin to foreskin1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/21/10576\" title=\"picture 9B\">",
"      Apply pin to foreskin2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/28/18880\" title=\"picture 9C\">",
"      Gomco clamp with safety pin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/61/26591\" title=\"picture 10\">",
"      Gomco on glans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/53/15199\" title=\"picture 11\">",
"      Circumcised penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/2/5155\" title=\"picture 12A\">",
"      Petroleum gauze",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/9/17552\" title=\"picture 12B\">",
"      Petroleum gauze dressing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/3/22591\" title=\"picture 13\">",
"      Mogan clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/28/31183\" title=\"picture 14\">",
"      Mogan clamp applied to foreskin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/26/8608\" title=\"picture 15\">",
"      Cutting foreskin off Mogan clam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/0/20492\" title=\"table 1A\">",
"      Circumcision info sheet A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/24/9612\" title=\"table 1B\">",
"      Circumcision info sheet B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4903?source=related_link\">",
"      Complications of circumcision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41705?source=related_link\">",
"      Neonatal circumcision: Risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=related_link\">",
"      Patient information: Circumcision in baby boys (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/36/29249?source=related_link\">",
"      Patient information: Circumcision in baby boys (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15257="Treatment and prognosis of uterine leiomyosarcoma";
var content_f14_57_15257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of uterine leiomyosarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Nadeem R Abu-Rustum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Martee L Hensley, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15257/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/57/15257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyosarcoma (LMS) is a rare uterine malignancy that arises from the smooth muscle of the uterine wall. Compared to other types of uterine cancers, LMS is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/1\">",
"     1",
"    </a>",
"    ]. Tumor grade and other histologic features can influence clinical behavior of the tumors, and may be important determinants of treatment recommendations. Whenever possible, women with uterine sarcomas should be referred to specialty centers with expertise in their diagnosis and management. &nbsp;",
"   </p>",
"   <p>",
"    This topic will cover the treatment approach to high grade uterine LMS. The classification, clinical manifestations, diagnosis, and staging of other uterine sarcomas are covered separately. Treatment of other types of uterine sarcomas is also covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"       \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=see_link\">",
"       \"Classification and treatment of endometrial stromal tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=see_link\">",
"       \"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=see_link\">",
"       \"Classification and treatment of endometrial stromal tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107273789\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the diagnosis of uterine leiomyosarcoma (LMS) is made following hysterectomy or myomectomy for presumed benign uterine leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As an example, in one series of 106 women with uterine sarcoma, 65 percent of those with LMS were preoperatively diagnosed with a benign leiomyoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/3\">",
"     3",
"    </a>",
"    ]. The sequence of events leading to the diagnosis may influence the treatment approach.",
"   </p>",
"   <p>",
"    The diagnosis of LMS and differentiating benign leiomyomas from LMS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H15#H15\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12821860\">",
"    <span class=\"h2\">",
"     Preoperative or intraoperative diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMS is typically diagnosed postoperatively, but in rare cases it is diagnosed with endometrial sampling preoperatively or with frozen section intraoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H16656415#H16656415\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107273603\">",
"    <span class=\"h3\">",
"     Disease confined to the uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with uterine LMS that is confined to the uterus at time of surgery, we proceed with a total hysterectomy. Several case series support the role of primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In the largest series involving 46 patients with LMS, complete cytoreduction was significantly associated with disease-free survival (p=0.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts also perform a bilateral salpingo-oophorectomy (BSO) at the time of total hysterectomy, particularly for menopausal or perimenopausal women. However, it is not clear if BSO influences survival in women with newly diagnosed LMS. (See",
"    <a class=\"local\" href=\"#H107274058\">",
"     'Premenopausal women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107273610\">",
"    <span class=\"h3\">",
"     Disease extending beyond the uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with extrauterine disease, the role of surgery is controversial. Our approach depends on whether the patient is a surgical candidate and whether or not a complete resection of disease is feasible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with disease confined to the pelvis (stage II) or the abdomen (stage III) (",
"      <a class=\"graphic graphic_table graphicRef59860 \" href=\"UTD.htm?35/35/36414\">",
"       table 1",
"      </a>",
"      ), we perform a total hysterectomy with BSO and surgical cytoreduction of intraabdominal and retroperitoneal disease. Although the data are limited to small patient series, an optimal cytoreduction (to no gross residual disease) is associated with improved overall survival compared to women with residual disease at the end of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      For women with disease not amenable to an optimal cytoreduction (including those with metastatic disease extending beyond the peritoneal cavity), there is no benefit to surgery. In at least one study, the presence of residual disease following surgery was associated with a poor prognosis compared to a complete cytoreduction [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, surgery may delay the start of systemic treatment. Therefore, in the absence of high quality data showing a benefit to surgical cytoreduction, we initiate medical therapy rather than surgical cytoreduction. (See",
"      <a class=\"local\" href=\"#H12822955\">",
"       'Metastatic disease'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      However, surgery may be reasonable in the following scenarios:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Total hysterectomy may serve as palliation for women experiencing significant pelvic symptoms (ie, pain or vaginal bleeding).",
"     </li>",
"     <li>",
"      Total hysterectomy and resection of metastatic disease may be considered for selected patients with a relatively low disease burden beyond the peritoneal cavity (eg, isolated metastatic disease in the lung or liver). Complete resection in these patients may be possible with limited morbidity. (See",
"      <a class=\"local\" href=\"#H12822955\">",
"       'Metastatic disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193031386\">",
"    <span class=\"h2\">",
"     Postoperative diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are diagnosed with LMS after total hysterectomy (on final pathologic review), we do not perform a second surgical procedure for the sole purpose of staging. Instead, we perform a postoperative computed tomography (CT) of the chest, abdomen, and pelvis to help guide postoperative treatment.",
"   </p>",
"   <p>",
"    For patients who underwent a hysterectomy (or myomectomy) alone and who are surgical candidates, however, a second surgical procedure is reasonable in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who are premenopausal and do not desire ovarian preservation, we perform a BSO.",
"     </li>",
"     <li>",
"      For women who underwent a supracervical hysterectomy (or myomectomy), we suggest removal of the cervix or hysterectomy combined with a BSO.",
"     </li>",
"     <li>",
"      For women in whom the tumor was morcellated, we suggest surgical exploration and staging to ensure any residual peritoneal disease is resected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274757\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR LYMPHADENECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform a pelvic lymphadenectomy for women if the pelvic nodes are palpably enlarged intraoperatively or there is evidence of extrauterine disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Women with leiomyosarcoma (LMS) confined to the uterus have a low incidence of lymph node involvement. This was illustrated in a Gynecologic Oncology Group (GOG) study of 59 women with clinical stage I or II LMS (all of whom underwent surgical staging), in which the incidence of lymph node metastases was less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/10\">",
"     10",
"    </a>",
"    ]. In another series of 37 patients with LMS who underwent nodal sampling, only three patients had positive nodes and in all cases they were clinically suspicious at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522011517\">",
"    <span class=\"h1\">",
"     ROLE OF IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 33 percent of patients with newly diagnosed uterine leiomyosarcoma (LMS) present with distant metastatic disease (stage IVB), most commonly involving the liver, lung, or upper abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/2,6,8,11,12\">",
"     2,6,8,11,12",
"    </a>",
"    ]. Therefore, all patients should undergo imaging to rule out metastatic disease following pathologic confirmation of the diagnosis.",
"   </p>",
"   <p>",
"    There are no data on the ideal imaging evaluation for women with LMS. Chest x-ray, CT, magnetic resonance imaging (MRI), and positron emission tomography (PET scans) are all used to evaluate for metastatic disease for soft tissue sarcomas. We perform a CT perioperatively in all women diagnosed with LMS. There are no data on the utility of PET in perioperative staging of LMS, and the data on PET for the detection of recurrence are limited to retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. There is no evidence that it provides more useful information than either CT or MRI. Further discussion on the imaging evaluation of sarcomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227142#H12227142\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213141155\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyosarcoma (LMS) is staged using the 2009 FIGO staging system (",
"    <a class=\"graphic graphic_table graphicRef59860 \" href=\"UTD.htm?35/35/36414\">",
"     table 1",
"    </a>",
"    ). This differs from the staging system used for adenosarcoma, endometrial adenocarcinoma, and uterine carcinosarcoma (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/15\">",
"     15",
"    </a>",
"    ]. For example, abdominal involvement is considered T3 disease for LMS, but is considered T4b disease for endometrial adenocarcinoma.",
"   </p>",
"   <p>",
"    The FIGO staging system does not predict the prognosis for overall survival for patients with uterine LMS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/16\">",
"     16",
"    </a>",
"    ]. A nomogram that incorporates patient age, tumor size, grade, local extension, distant metastases, and mitotic rate as key variables may be prognostically more useful [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12824641\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9939629\">",
"    <span class=\"h1\">",
"     ADJUVANT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy, radiation, and combined modality treatment (chemotherapy plus radiation therapy [RT]) are sometimes considered following surgery for leiomyosarcoma (LMS). However, whether any form of adjuvant therapy improves survival compared with observation is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H677536887\">",
"    <span class=\"h2\">",
"     Early stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with early stage (stage I or II) uterine LMS, is not clear if any intervention improves the survival outcomes compared to post-surgical surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Therefore, for women with surgical stage I or II LMS, we suggest observation rather than adjuvant therapy. The data evaluating chemotherapy and RT for early stage LMS is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28816387\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28815849\">",
"    <span class=\"h4\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GOG conducted a phase III trial in 156 women with stage I or II uterine sarcoma (all histologies) who were randomly assigned treatment with postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or no further treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/17\">",
"     17",
"    </a>",
"    ]. Although women treated with doxorubicin had a lower recurrence rate compared to those not treated with chemotherapy (41 versus 53 percent), this was not statistically significant. In addition, adjuvant doxorubicin had no impact on progression-free or overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28815963\">",
"    <span class=\"h4\">",
"     Docetaxel and gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not comprised exclusively of patients with early stage disease, fixed-dose rate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (900",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 90 minutes on days 1 and 8) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 8) administered with hematopoietic growth factor support was evaluated in a trial involving 25 women with completed resected, high grade uterine LMS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/18\">",
"     18",
"    </a>",
"    ]. Among women with stage I or II disease, 59 percent remained progression-free at three years (median, 39 months). Of note, at a median follow-up of 49 months, the two-year progression-free survival (PFS) rate was 45 percent and median PFS was 13 months for the entire cohort. Given the lack of a control arm and the small number of patients treated, the significance of these findings is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28816005\">",
"    <span class=\"h4\">",
"     Docetaxel and gemcitabine followed by doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, multi-institutional phase II trial (SARC 005) enrolled 47 women with uterus-limited high grade LMS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/21\">",
"     21",
"    </a>",
"    ]. All patients received four cycles of fixed dose rate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , followed by four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and were evaluated for disease recurrence by imaging approximately every three months. Of those enrolled, 89 percent of patients received all eight planned cycles. The median time to recurrence was 27 months and the three-year PFS rate was 57 percent.",
"   </p>",
"   <p>",
"    Whether adjuvant chemotherapy improves survival outcomes remains uncertain. A prospective randomized trial is being conducted by the GOG in collaboration with the EORTC and Cancer Research-UK which compares the SARC005 regimen to observation in women who have undergone surgical resection of high-grade FIGO stage I uterine leiomyosarcoma (",
"    <a class=\"external\" href=\"file://cancer.gov/clinicaltrials/GOG-0277\">",
"     GOG 277",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28815876\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of adjuvant RT has no impact on survival outcomes for women with early stage LMS. This was demonstrated in a European Organization for Research and Treatment of Cancer randomized trial (EORTC 55874), which enrolled women with stage I and II uterine sarcomas and randomly assigned them to treatment with postoperative RT or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/20\">",
"     20",
"    </a>",
"    ]. Among women with LMS (n=103), pelvic RT resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant differences in either local or distant progression rates compared with observation",
"     </li>",
"     <li>",
"      A trend towards a reduction in overall survival (HR for survival 0.64, 95% CI 0.36-1.14), although this did not reach statistical significance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28815942\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with intra-abdominal involvement of disease (stage III) or distant metastases (stage IV) who have undergone complete resection of disease have a high risk of disease progression following surgery alone. Therefore, we offer adjuvant chemotherapy rather than postoperative surveillance although whether treatment improves survival has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107273754\">",
"    <span class=\"h3\">",
"     Docetaxel and gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one prospective study evaluated chemotherapy following a complete cytoreduction for uterine leiomyosarcoma. As discussed above, 25 women with stage I to IV LMS received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    on a GOG trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/18\">",
"     18",
"    </a>",
"    ]. However, this study lacked a control arm and it remains unclear whether treatment results in an improvement in survival. (See",
"    <a class=\"local\" href=\"#H28815963\">",
"     'Docetaxel and gemcitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H677536961\">",
"    <span class=\"h3\">",
"     Combined modality treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with advanced LMS, the administration of combined modality treatment (eg, pelvic radiation plus chemotherapy) is investigational. One study randomly assigned 81 patients with uterine sarcoma (53 with LMS) to treatment with pelvic RT with or without combination chemotherapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (API) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared to pelvic RT, the addition of API was associated with the following non-statistically significant trends:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower incidence of recurrence (39 versus 62 percent)",
"     </li>",
"     <li>",
"      Higher progression-free survival at three years (52 versus 41 percent)",
"     </li>",
"     <li>",
"      Improvement in overall survival at three years (80 versus 67 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with API was associated with serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicity, including neutropenia (84 percent), febrile neutropenia (22 percent), and nausea and vomiting (24 percent). Two treatment-related deaths due to febrile neutropenia also occurred. The study was closed early due to poor accrual. Until further data become available, the administration of combined modality treatment should not be used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12824634\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyosarcoma (LMS) is an aggressive tumor with a high risk of relapse, even when confined to the uterus at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, we perform a physical exam every three to four months and chest, abdomen, pelvic imaging every three to four months for two to three years, then every 6 to 12 months for the next two years. Although there are no data that surveillance improves outcomes for women with LMS, these recommendations are consistent with surveillance guidelines of the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12824641\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with leiomyosarcoma (LMS) have a poor prognosis regardless of stage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/11,24\">",
"     11,24",
"    </a>",
"    ]. In the largest study of women with LMS that included 1396 patients (71 percent with stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    disease), the five-year disease specific survival (DSS) was 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/11\">",
"     11",
"    </a>",
"    ]. Stratified by stage, the five-year disease specific overall survival for stage I, II, III, and IV disease was 76, 60, 45, and 29 percent, respectively. Factors associated with worse disease-specific survival were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher tumor grade (HR 1.83, 95% CI 1.43-2.34)",
"     </li>",
"     <li>",
"      Higher disease stage (HR 1.58, 95% CI 1.47-1.71)",
"     </li>",
"     <li>",
"      African American race (HR 1.45, 95% CI 1.09-1.94)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the prognostic significance of grade, there is no single, universally accepted grading system for uterine LMS. Low grade leiomyosarcomas and smooth muscle neoplasms that do not meet diagnostic criteria for uterine LMS (eg, smooth muscle tumors of uncertain malignant potential [STUMP]) may follow a more favorable disease course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H8#H8\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Leiomyosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither FIGO nor AJCC staging performs well in terms of providing prognostic information for overall survival in uterine LMS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/16\">",
"     16",
"    </a>",
"    ]. A",
"    <a class=\"external\" href=\"file://nomograms.mskcc.org/Uterine/LeiomyosarcomaSurvival.aspx\">",
"     nomogram",
"    </a>",
"    has been developed that incorporates patient age, tumor size, grade, local extension, distant metastases, and mitotic rate as key variables. This nomogram performs better than FIGO and AJCC staging in terms of predicting five-year overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274051\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274058\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women uterine leiomyosarcoma (LMS) may wish to retain their ovaries for fertility preservation. In addition, oophorectomy will result in these patients will result in premature menopause, which may impact quality of life.",
"   </p>",
"   <p>",
"    Most experts perform a bilateral salpingo-oophorectomy (BSO) as part of standard surgical treatment. However, data are limited regarding the impact of BSO on LMS survival. At least 40 percent of uterine leiomyosarcomas (LMS) express estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, in one study of 341 women who were &lt;50 years old and had stage I or II disease at diagnosis, there was no difference in five-year disease-free survival in those who did or did not undergo BSO [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/11\">",
"     11",
"    </a>",
"    ]. This study was limited because the number of women who had previously had both ovaries removed was not reported.",
"   </p>",
"   <p>",
"    In the absence of randomized trial data addressing the impact of BSO on survival in LMS, recommendations regarding BSO must be individualized. One reasonable approach is to recommend BSO for patients whose FIGO stage I uterine LMS is estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone-receptor-positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274094\">",
"    <span class=\"h2\">",
"     Medically inoperable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients who are not candidates for surgical resection due to comorbidity or poor performance status must be individualized. Given the poor prognosis for patients with uterine LMS regardless of stage, non-surgical treatment is palliative, not curative. Therefore, careful consideration of the benefits (eg, control of pain or bleeding) must be weighed against the toxicities of medical treatment. The treatment approach to medically inoperable patients mirrors that of women with metastatic disease. (See",
"    <a class=\"local\" href=\"#H12822955\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyosarcoma (LMS) most commonly metastasizes to the lungs, liver, abdomen, pelvis, and pelvic or paraaortic lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/29\">",
"     29",
"    </a>",
"    ]. Bone and brain metastases are less common sites of involvement. The approach to treatment depends on whether or not disease is surgically resectable. This is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12822947\">",
"    <span class=\"h2\">",
"     Local recurrence or oligometastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized recurrences or limited metastatic disease, surgical resection may offer a survival advantage and should be offered to appropriately selected patients. However, the data supporting this approach are limited to small series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one series of 31 patients with pulmonary metastases, for example, metastasectomy resulted in a median overall survival of 70 months.",
"   </p>",
"   <p>",
"    The best candidates for this approach are those who recur after a prolonged progression-free interval (at least 12 to 18 months) and with an isolated site of recurrence that is amenable to complete resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are not surgical candidates, radiation therapy (RT) is an alternative treatment option for locally recurrent disease. Its application in uterine sarcomas is similar to the approach in endometrial adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=see_link&amp;anchor=H2110943027#H2110943027\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\", section on 'No prior radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach to localized metastatic disease is radiofrequency ablation (RFA). Although no randomized trials have been performed, RFA may successfully treat individual lesion that are small (generally under 4 cm) and accessible (generally not near major blood vessels) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/33\">",
"     33",
"    </a>",
"    ]. Appropriate candidates for RFA have single site disease that is accessible for ablation and relapsed after a prolonged disease-free interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12822955\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with metastatic disease who are not surgical candidates, treatment is given with palliative intent. Chemotherapy is a reasonable option for women with metastatic LMS who maintain a good performance status and in whom organ function permits the use of cytotoxic chemotherapy. For other patients, we suggest palliative care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107275062\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is sufficient activity of chemotherapy to support its use in women with recurrent disease, although there is no preferred agent or regimen. In general, management of recurrent uterine sarcoma is similar to treatment of metastatic soft tissue sarcomas arising at other sites, although some data suggest that uterine LMS may be more sensitive to some chemotherapy regimens than other non-LMS histology soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2005 systematic review of 27 studies (including three randomized trials) that looked at the role of chemotherapy for advanced uterine sarcoma concluded that chemotherapy was a reasonable option for women with symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/34\">",
"     34",
"    </a>",
"    ]. Of the available options, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    because of the high objective response rates demonstrated in prospective clinical trials as a first- or second-line therapy. For patients who progress after docetaxel and gemcitabine, further treatment is based on patient preference, organ function, and performance status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274208\">",
"    <span class=\"h4\">",
"     Docetaxel and gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of fixed-dose rate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    has been evaluated as a first- and second-line treatment for metastatic uterine LMS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In GOG 87L, 42 women were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      until disease progression or unacceptable toxicity. The overall response rate (ORR) was 36 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/35\">",
"       35",
"      </a>",
"      ]. The major toxicity was myelosuppression with grade 3 or 4 neutropenia occurring in 17 to 20 percent of patients. Other side effects included fatigue (74 percent), GI complaints (14 percent), and pulmonary toxicity (9 percent).",
"     </li>",
"     <li>",
"      In GOG 131G, 51 patients who had disease progression after first-line treatment (90 percent had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ) received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/36\">",
"       36",
"      </a>",
"      ]. The ORR was 27 percent and 52 percent were progression free at six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274217\">",
"    <span class=\"h4\">",
"     Doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) is an effective drug in metastatic LMS. In one GOG study, 104 chemotherapy na&iuml;ve women were randomly assigned to treatment with doxorubicin with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/37\">",
"     37",
"    </a>",
"    ]. The ORR was 19 percent in both arms. Overall survival was also similar (median, 12 months with doxorubicin versus 11 months with the combination). The combination of doxorubicin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    achieved objective response in 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274224\">",
"    <span class=\"h4\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over 30 minutes on a three-week",
"    <span class=\"nowrap\">",
"     on/one-week",
"    </span>",
"    off schedule) was evaluated in a GOG study involving 44 women and resulted in an ORR of 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/39\">",
"     39",
"    </a>",
"    ]. Serious (grade 4) toxicity consisted of neutropenia (16 percent), nausea and vomiting (4.5 percent), and rash (2.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274436\">",
"    <span class=\"h4\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV for five days with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    , every three weeks) was evaluated in a GOG study of 56 patients and resulted in an ORR of 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/40\">",
"     40",
"    </a>",
"    ]. A second GOG study evaluated ifosfamide plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    that resulted in a 30 percent ORR, although the duration of response was only four months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274250\">",
"    <span class=\"h4\">",
"     Trabectedin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41798?source=see_link\">",
"     Trabectedin",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over 24 hours every three weeks) is a cytotoxic agent approved for use in Europe and other countries, but not currently in the United States, for advanced soft tissue sarcoma after failure of anthracycline-based treatment.",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    in LMS has not been clearly defined. In a phase II GOG study that enrolled 20 patients, only two responses were observed; however, median progression free survival (PFS) was 5.8 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/41\">",
"     41",
"    </a>",
"    ]. A retrospective study of 66 patients with previously treated LMS reported an overall response rate of 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/42\">",
"     42",
"    </a>",
"    ]. However, median PFS was only three months. Trabectedin is currently being compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    in a",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01343277\">",
"     phase III trial",
"    </a>",
"    for patients with leiomyosarcoma or liposarcoma for patients who have progressed after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -base therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274236\">",
"    <span class=\"h4\">",
"     Dacarbazine and temozolamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     Dacarbazine",
"    </a>",
"    (1200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) has modest activity in soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (50 to 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    taken orally every day for six out of eight weeks), an oral prodrug of dacarbazine also appears to be active, although the data are quite limited [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H463025574\">",
"    <span class=\"h4\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    is an oral multi-kinase inhibitor that was approved in the US in April 2012 for the treatment of metastatic soft tissue sarcomas after disease progression on an anthracycline-based therapy. The European Organization for the Research and Treatment of Cancer conducted a phase III trial that included 372 patients who were randomly assigned to treatment with pazopanib (800 mg once daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/46\">",
"     46",
"    </a>",
"    ]. Compared to placebo, pazopanib resulted in an improvement in median PFS (5 versus 2 months, HR 0.31, 95% CI 0.67-1.11) but no significant difference in median OS (13 versus 11 months, HR 0.86, 95% CI 0.67-1.11). The objective response rate to pazopanib was six percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/46\">",
"     46",
"    </a>",
"    ]. Further discussion of this trial and systemic treatment of metastatic soft tissue sarcomas in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H8828453#H8828453\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Pazopanib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107274243\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aromatase inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    ) have been evaluated for patients with LMS with ORR of less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15257/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, given the minimal toxicity and high rate of compliance with hormone treatment, it may be a reasonable option for asymptomatic patients with low volume disease burden and hormone-receptor positive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine leiomyosarcoma (LMS) is a rare and aggressive uterine malignancy that arises from the smooth muscle of the uterine wall. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women in whom the diagnosis of LMS is made preoperatively (see",
"      <a class=\"local\" href=\"#H12821860\">",
"       'Preoperative or intraoperative diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend a total hysterectomy for women with disease confined to the uterus rather than non-operative therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest a bilateral salpingo-oophorectomy (BSO) also be performed at the time of surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H107273603\">",
"       'Disease confined to the uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with disease that has spread beyond the uterus but is confined to the peritoneal cavity, we suggest surgical cytoreduction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with metastatic disease that cannot be surgically resected or has spread beyond the peritoneal cavity, we suggest the administration of chemotherapy rather than RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H107273610\">",
"       'Disease extending beyond the uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We limit pelvic lymphadenectomy to women with pelvic nodes that are palpably enlarged intraoperatively or those with extrauterine disease. (See",
"      <a class=\"local\" href=\"#H107274757\">",
"       'Indications for lymphadenectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women whose hysterectomy specimen is found postoperatively to be LMS, a second surgical procedure for the sole purpose of staging is not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a BSO for premenopausal women who do not desire ovarian preservation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women who underwent a supracervical hysterectomy (or myomectomy), we suggest removal of the cervix or hysterectomy combined with a BSO (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women in whom the tumor was morcellated at the time of surgery, we suggest surgical exploration and staging (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with newly diagnosed uterine LMS that is limited to the body of the uterus, we suggest observation rather than adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend against pelvic RT in these patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Enrollment in clinical trials investigating the role of adjuvant therapy should be encouraged. (See",
"      <a class=\"local\" href=\"#H677536887\">",
"       'Early stage disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage III or IV LMS, we suggest chemotherapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28815942\">",
"       'Advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all women with newly diagnosed LMS, surveillance examinations and imaging is required due to the high risk of relapse, regardless of stage. (See",
"      <a class=\"local\" href=\"#H12824634\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized recurrence or limited metastatic disease that is amenable to complete resection, we suggest surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12822947\">",
"       'Local recurrence or oligometastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with metastatic, unresectable disease, treatment is administered with palliative intent. Chemotherapy is a reasonable option for women with metastatic LMS who maintain a good performance status and in whom organ function permits the use of cytotoxic chemotherapy. For other patients, we suggest palliative care.",
"     </li>",
"     <li>",
"      For women with metastatic disease who are chemotherapy naive, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H107274208\">",
"       'Docetaxel and gemcitabine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who progress after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , a choice of chemotherapy is based on patient preference, organ function, and performance status. For women with hormone receptor-positive leiomyosarcoma, endocrine therapy is an additional treatment option. (See",
"      <a class=\"local\" href=\"#H12822955\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/1\">",
"      D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/2\">",
"      Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/3\">",
"      Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/4\">",
"      Nassar OA, Abdul Moaty SB, Khalil el-SA, et al. Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst 2010; 22:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/5\">",
"      Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol 2008; 134:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/6\">",
"      Dinh TA, Oliva EA, Fuller AF Jr, et al. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004; 92:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/7\">",
"      Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008; 18:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/8\">",
"      Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993; 50:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/9\">",
"      Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003; 91:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/10\">",
"      Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993; 71:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/11\">",
"      Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/12\">",
"      Sandruck J, Escobar P, Lurain J, Fishman D. Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature. Gynecol Oncol 2004; 92:701.",
"     </a>",
"    </li>",
"    <li>",
"     Engle DB, Smiley LM, Baum SL, Wellman GP.  Positron Emission Tomography in detection of metastatic leiomyosarcoma in a postoperative patient: a case report. Proc Obstet Gynecol. 2011 July;2(1):Article 14[5 p]. ir.uiowa.edu/cgi/viewcontent.cgi?article=1111&amp;context=pog (Accessed on August 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/14\">",
"      Sung PL, Chen YJ, Liu RS, et al. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Eur J Gynaecol Oncol 2008; 29:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/15\">",
"      Corrigendum to &ldquo;FIGO staging for uterine sarcomas&rdquo; [International Journal of Gynecology and Obstetrics (2009) 104:179]. Int J Gynaecol Obstet 2009; 106:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/16\">",
"      Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol 2009; 27:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/17\">",
"      Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 3:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/18\">",
"      Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009; 112:563.",
"     </a>",
"    </li>",
"    <li>",
"     Hensley ML, Wathen R, Maki RG, et al. Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005 (abstract #10021). J Clin Oncol 2010; 28:15s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/20\">",
"      Reed NS, Mangioni C, Malmstr&ouml;m H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/21\">",
"      Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: Results of a phase 2 trial (SARC 005). Cancer 2013; 119:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/22\">",
"      Pautier P, Floquet A, Berton-Rigaud D, Piperno-Neumann S. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients (abstract 10022). J Clin Oncol 2011; S:10022.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/24\">",
"      Zivanovic O, Jacks LM, Iasonos A, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012; 118:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/25\">",
"      Iasonos A, Keung EZ, Zivanovic O, et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/26\">",
"      Leitao MM Jr, Hensley ML, Barakat RR, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 2012; 124:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/27\">",
"      Kelley TW, Borden EC, Goldblum JR. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 2004; 12:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/28\">",
"      Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004; 101:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/29\">",
"      Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993; 66:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/30\">",
"      Anraku M, Yokoi K, Nakagawa K, et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 2004; 127:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/31\">",
"      Burt BM, Ocejo S, Mery CM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg 2011; 92:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/32\">",
"      Clavero JM, Deschamps C, Cassivi SD, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg 2006; 81:2004.",
"     </a>",
"    </li>",
"    <li>",
"     O'Cearbhaill RE, Maki RG, Zheng J, et al. Evaluation of the role of thermal ablation in the treatment of soft tissue sarcomas. 2009 Connective Tissue Oncology Society Meeting, Miami, FL. #39259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/34\">",
"      Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005; 97:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/35\">",
"      Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/36\">",
"      Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008; 109:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/37\">",
"      Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/38\">",
"      Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/39\">",
"      Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004; 92:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/40\">",
"      Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/41\">",
"      Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012; 124:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/42\">",
"      Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol 2011; 123:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/43\">",
"      Garc&iacute;a-Del-Muro X, L&oacute;pez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/44\">",
"      Anderson S, Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005; 98:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/45\">",
"      Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/46\">",
"      van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/47\">",
"      Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009; 115:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/48\">",
"      Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007; 110:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15257/abstract/49\">",
"      O'Cearbhaill R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol 2010; 116:424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3188 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15257=[""].join("\n");
var outline_f14_57_15257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107273789\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12821860\">",
"      Preoperative or intraoperative diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107273603\">",
"      - Disease confined to the uterus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107273610\">",
"      - Disease extending beyond the uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193031386\">",
"      Postoperative diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107274757\">",
"      INDICATIONS FOR LYMPHADENECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522011517\">",
"      ROLE OF IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213141155\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9939629\">",
"      ADJUVANT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H677536887\">",
"      Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28816387\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28815849\">",
"      Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28815963\">",
"      Docetaxel and gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28816005\">",
"      Docetaxel and gemcitabine followed by doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28815876\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28815942\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107273754\">",
"      - Docetaxel and gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H677536961\">",
"      - Combined modality treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12824634\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12824641\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107274051\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107274058\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107274094\">",
"      Medically inoperable patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12822947\">",
"      Local recurrence or oligometastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12822955\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107275062\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274208\">",
"      Docetaxel and gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274217\">",
"      Doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274224\">",
"      Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274436\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274250\">",
"      Trabectedin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H107274236\">",
"      Dacarbazine and temozolamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H463025574\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107274243\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/35/36414\" title=\"table 1\">",
"      Staging uterine sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43549\" title=\"table 2\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classification-and-treatment-of-endometrial-stromal-tumors?source=related_link\">",
"      Classification and treatment of endometrial stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44585?source=related_link\">",
"      Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=related_link\">",
"      Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15258="Overview of care of the adult kidney transplant recipient";
var content_f14_57_15258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of care of the adult kidney transplant recipient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Anil Chandraker, MD, FASN, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/57/15258/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/57/15258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25669033\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney transplantation is the treatment of choice for end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/1\">",
"     1",
"    </a>",
"    ]. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, patients require close follow-up after transplantation since they are on complex immunosuppressive regimens that render them susceptible to infection, malignancy, and cardiovascular disease. In addition, patients often have multiple co-morbidities due to, or as a cause of, their underlying end-stage renal disease.",
"   </p>",
"   <p>",
"    Whereas patients are generally followed by a transplant specialist for the first three to six months following transplant, thereafter they may be seen primarily by a general nephrologist or internist, who are often able to address existing comorbidities. Whether a patient is followed by a transplant nephrologist, general nephrologist, or internist often depends upon the availability of services in proximity to the patient. While many believe that transplant nephrologists should be directly involved in care of transplant recipients for the life of the graft this is often not practical. Communication between the internist, or community-based nephrologist, and the transplant center is important for optimal care of the patient however.",
"   </p>",
"   <p>",
"    This topic reviews the general medical care of the kidney transplant recipient including recommendations for monitoring allograft function and minimizing the risk of infections, malignancies, bone disease, cardiovascular disease, and diabetes. Common medical problems encountered after transplantation are also discussed.",
"   </p>",
"   <p>",
"    Maintenance immunosuppressive therapy, allograft dysfunction, and patient survival following transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific complications of transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20579?source=see_link\">",
"     \"Urinary tract infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=see_link\">",
"     \"Hepatitis B virus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669040\">",
"    <span class=\"h1\">",
"     ROUTINE FOLLOW UP AND LABORATORY MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are followed by a transplant nephrologist for at least the first three to six months following transplantation. The frequency of followup varies between centers and depending on the stability of the patient. Immunosuppressive therapy is gradually reduced during the first three to six months to avoid adverse medication effects while still preventing rejection.",
"   </p>",
"   <p>",
"    Beyond 6 to 12 months, patients may be followed by an internist or general nephrologist in consultation with a transplant nephrologist, since the risks of complications such as rejection are thought to have decreased beyond this time. Patients continue to require close monitoring to ensure that the graft is functioning optimally and to assess for complications due to side effects of immunosuppressive medications, such as infection or malignancy.",
"   </p>",
"   <p>",
"    In addition, patients may have complications of reduced renal function, such as anemia and bone disease. Patients are at high risk for cardiovascular complications because of their reduced renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    predisposing conditions such as diabetes mellitus.",
"   </p>",
"   <p>",
"    The type and frequency of laboratory testing varies from center to center. A typical monitoring scheme is presented in (",
"    <a class=\"graphic graphic_table graphicRef80400 \" href=\"UTD.htm?31/6/31851\">",
"     table 1",
"    </a>",
"    ). At some centers laboratory tests are checked more frequently and are in some cases independent of patient visits (as an example, weekly for 16 weeks and then every other week until one year from transplantation and then monthly for life).",
"   </p>",
"   <p>",
"    The following laboratory tests should be checked regularly:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum creatinine, glucose and electrolytes",
"     </li>",
"     <li>",
"      Twelve-hour trough",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      levels (some centers follow peak levels)",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    trough levels should be followed for patients who are taking these agents.",
"   </p>",
"   <p>",
"    In addition, urine and blood tests to screen for BK virus are done monthly at months 1 to 6 and at months 9, 12, 18, and 24, and for cause as part of the evaluation of an elevated serum creatinine at any time post-transplantation. Some centers do more frequent surveillance.",
"   </p>",
"   <p>",
"    All patients should have a fasting blood glucose measured weekly during the first four weeks posttransplant, then at three and six months post-transplant, and then yearly. A hemoglobin A1c can be checked after three months post-transplant, particularly if it is difficult to obtain fasting plasma-glucose levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link&amp;anchor=H23#H23\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We check lipid profiles (complete fasting lipid profile including total cholesterol, LDL, HDL, and triglycerides) every three months after transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid abnormalities after renal transplantation\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parathyroid hormone (PTH) and vitamin D levels should be measured every 6 to 12 months. Some, though not all, clinicians check bone mineral density prior to transplantation and at three months following transplantation using dual energy X&ndash;ray absorptiometry (DEXA). There are no reliable studies that have shown that low bone mineral density is predictive of adverse outcomes among transplant recipients, and the optimal treatment for transplant recipients who have abnormal or worsening bone mineral density studies is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients are screened for abnormal proteinuria at 3, 6, and 12 months, and every 12 months thereafter, or at every clinic visit. The method of screening varies between centers. Whereas some clinicians measure protein-to-creatinine ratios among all patients, others obtain urinalyses in all patients and measure protein-to-creatinine ratios only in patients who have greater than 1+ proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .) Among patients with a history of proteinuric kidney disease, protein to creatinine ratios may be checked more frequently to monitor for recurrence of the original glomerular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39367?source=see_link\">",
"     \"IgA nephropathy: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=see_link\">",
"     \"Membranoproliferative glomerulonephritis: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=see_link\">",
"     \"Anti-GBM antibody disease: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=see_link\">",
"     \"Membranous nephropathy and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3167242\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression therapy may be divided into induction and maintenance regimens. Induction therapy is started either pre- or intraoperatively and includes biologic antibodies, calcineurin inhibitors, antimetabolites or antiproliferative agents, and glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance immunosuppression regimens include steroids, calcineurin inhibitors and an antiproliferative or antimetabolite agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some centers will try to reduce glucocorticoids or use glucocorticoid-free protocols among patients who have received induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Such an approach may have a beneficial impact on blood pressure, glycemic control, bone disease, and lipid profiles. However, glucocorticoid-free protocols may increase the risk of chronic allograft nephropathy and we thus generally continue low-dose glucocorticoids indefinitely among most patients. This issue is discussed in depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=see_link\">",
"     \"Withdrawal or avoidance of glucocorticoids after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common calcineurin inhibitors include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Although monitoring of trough concentrations (12 hours post-dose) of cyclosporine is common practice, there is a poor correlation between clinical outcome and drug exposure as assessed using this strategy. Some centers use the two-hour post-dose cyclosporine level (C2) among kidney transplant recipients since these concentrations may correlate more closely with exposure, with higher C2 concentrations being associated with decreased acute rejection rates in the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our C2 target concentrations are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      800 to 1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in months one to three after transplantation",
"     </li>",
"     <li>",
"      400 to 600",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      for subsequent months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is utilized, doses are adjusted to attain target whole-blood trough concentrations of 8 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first three months, and 3 to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after this period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/9\">",
"     9",
"    </a>",
"    ]. When antilymphocyte depleting agents are used, we target tacrolimus to 7 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    during the first month and then 3 to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter. Dosing and levels may be affected by polymorphisms of the multidrug resistance-1 (P-glycoprotein, PGP) and CYP3A5 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the more prevalent use of induction therapy, many centers have attempted to use even lower levels of calcineurin inhibitors. The use of antiproliferative agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or mTOR inhibitors such as rapamycin may allow the safe reduction of calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link&amp;anchor=H15#H15\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\", section on 'Target levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After 6 to 12 months, immunosuppression regimens are generally stably maintained unless there is a specific reason such as infection or malignancy to reduce immunosuppression further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3167267\">",
"    <span class=\"h2\">",
"     Toxicity associated with common immunosuppressive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the drugs used for maintenance immunosuppression have well described side effects that vary in severity. Patients should be monitored for evidence of toxicity. Common side effects are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcineurin inhibitors: hirsutism, alopecia, neurologic disturbances, insomnia, hypertension, acute and chronic renal dysfunction, electrolyte abnormalities, post-transplant diabetes mellitus, hyperlipidemia, malignancies, and anemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      : GI disturbances.",
"     </li>",
"     <li>",
"      Rapamycin: pulmonary edema, hypertension, poor wound healing and joint pain anemia, edema, and hypertriglyceridemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      : leukopenia, hepatitis, and anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3167274\">",
"    <span class=\"h2\">",
"     Abnormal calcineurin inhibitor concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcineurin inhibitor (CNI) toxicity can cause kidney injury and hypertension. The prolonged use of calcineurin inhibitors may cause permanent fibrosis in the kidney. As discussed above, calcineurin inhibitor concentrations should be checked at regular intervals. (See",
"    <a class=\"local\" href=\"#H25669040\">",
"     'Routine follow up and laboratory monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An elevated CNI concentration that is reported as a result of routine testing requires prompt evaluation. Since the CNI concentration should reflect a C2 or trough level, it should first be confirmed that the blood was drawn at the correct time. If the blood was drawn correctly, other causes should be considered such as the patient taking the incorrect dose or a change in preparation of the immunosuppression agent (since generic forms of the medication may not be exactly equivalent). Another common reason for an increased CNI level is the administration of a drug or substance that interferes with the metabolism of CNIs (",
"    <a class=\"graphic graphic_table graphicRef60254 \" href=\"UTD.htm?28/45/29403\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H15#H15\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Increased cyclosporine levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflammation of the bowel wall associated with diarrhea can lead to increased concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Commonly patients will have CNI toxicity in the setting of therapeutic levels. In such cases, the CNI may be reduced or substituted, often with an increase of one of the other immunosuppressive medications. Altering the immunosuppressive regimen should only be done in consultation with the transplant nephrologist.",
"   </p>",
"   <p>",
"    Low CNI concentrations may result from starting another medication that influences the metabolism of the immunosuppressive CNI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H16#H16\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Decreased cyclosporine levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistently low CNI concentrations may also suggest noncompliance which should be addressed with the patient. Persistently low levels may result in rejection. In general, if levels of immunosuppressive drugs decrease below a specified target range the drug should be increased to bring the levels back into range. This is especially true in the first few months following transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155049\">",
"    <span class=\"h1\">",
"     COMMON MEDICAL PROBLEMS FOLLOWING TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transplant patient often has multiple medical issues that require evaluation by either the primary care provider or general nephrologist. These issues generally fall into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Issues related to the transplant kidney or to side effects of immunosuppression.",
"     </li>",
"     <li>",
"      Issues related to co-morbidities that led to the original kidney disease (such as diabetes, hypertension or glomerulonephritis).",
"     </li>",
"     <li>",
"      Issues related to end stage renal disease that preceded the transplant or to mild to moderately decreased kidney function resulting from the transplant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common problems include the onset of kidney dysfunction, (manifested by an elevated creatinine or development of microalbuminuria), diabetes, infectious disease, anemia, and cardiovascular disease. Malignancy may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3166750\">",
"    <span class=\"h2\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of renal dysfunction is usually revealed by routine laboratory monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1986915\">",
"    <span class=\"h3\">",
"     Increased creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients have a decreased glomerular filtration rate (GFR) compared to normal native kidney function following transplantation. The baseline creatinine following transplantation tends to be higher than 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (97",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for most patients, equivalent to an estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    Reasons for the modest decrease in GFR include the transplantation of a single kidney; ischemic injury (especially in the case of deceased donor kidneys); the use of expanded criteria donors (in which less than optimal kidneys are accepted for transplantation); and the use of calcineurin inhibitors which cause vasoconstriction.",
"   </p>",
"   <p>",
"    Among most patients, the serum creatinine remains stable from visit to visit. An abrupt increase in the serum creatinine of greater than 50 percent should be promptly evaluated.",
"   </p>",
"   <p>",
"    The possible causes of the increased creatinine include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prerenal (volume depletion due to vomiting or diarrhea) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Postrenal (obstruction) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"       \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Calcineurin nephrotoxicity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Allograft rejection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recurrence of glomerulonephritis (see appropriate topic reviews)",
"     </li>",
"     <li>",
"      De novo renal diseases such as acute tubular necrosis due to sepsis or nephrotoxins",
"     </li>",
"     <li>",
"      Drug-induced interstitial nephritis",
"     </li>",
"     <li>",
"      Infection including pyelonephritis or human polyomavirus type BK-associated interstitial nephritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"       \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal artery stenosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypertension after renal transplantation\", section on 'Renal artery stenosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An extensive history and physical exam should be carried out in patients with a worsening serum creatinine or GFR to exclude prerenal causes such as volume depletion due to vomiting or diarrhea. Medications should be reviewed for dose changes or the addition of new medications or herbal supplements that may either directly alter renal function or alter serum calcineurin inhibitor concentrations.",
"   </p>",
"   <p>",
"    The immunosuppressive regimen should be reviewed to determine whether the patient has missed any doses of their immunosuppressant medications.",
"   </p>",
"   <p>",
"    Laboratory investigation should include a serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    level, a urinalysis to exclude infection or new glomerular or interstitial disease, and a blood or urine BK viral load to exclude to BK reactivation, which is almost always a prerequisite to the development of polyoma virus associated-interstitial nephritis or nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A renal ultrasound should be done to exclude obstruction in patients who do not have an obvious cause of the increased creatinine.",
"   </p>",
"   <p>",
"    If there is still no explanation for the increased creatinine, a renal biopsy should be performed to determine the cause of the acute kidney injury. (See",
"    <a class=\"local\" href=\"#H25669078\">",
"     'Renal biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of specific disorders is discussed elsewhere. (See links provided above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669071\">",
"    <span class=\"h3\">",
"     Microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild proteinuria following transplantation predicts decreased long-term graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/15\">",
"     15",
"    </a>",
"    ] and is associated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Urinary protein excretion should be monitored by measuring the protein-to-creatinine ratio in a random urine sample for recurrence of glomerular diseases such as IgA nephropathy, focal segmental glomerulosclerosis, and diabetic nephropathy. Alternatively, some clinicians follow urinalyses in all patients and measure protein-to-creatinine ratios among patients with greater than 1+ protein on urinalysis. Proteinuria may also suggest acute allograft rejection or chronic allograft nephropathy. Persistent microalbuminuria may suggest any of the above disorders but may also suggest cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic renal allograft nephropathy\", section on 'Clinical manifestations, diagnosis, and pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A renal biopsy may be necessary to determine the cause of proteinuria. We biopsy most patients whose protein excretion exceeds 1",
"    <span class=\"nowrap\">",
"     g/d.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669078\">",
"    <span class=\"h3\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft biopsies are usually performed in the setting of some evidence of allograft dysfunction, such as an elevated serum creatinine, decreased urine output or worsening proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some centers perform protocol biopsies on all renal transplant patients at regular intervals, whereas others do protocol biopsies on all high-risk recipients, such as those with a history of BK virus; those at higher risk for recurrent disease or rejection; or highly sensitized patients.",
"   </p>",
"   <p>",
"    The risks of an allograft biopsy include bleeding, damage to other organs, infection and loss of allograft. Studies have reported a very low major complication rate (including transfusion requirement and catheterization) of between 0.4 and 1.0 percent, with only one graft lost in approximately 2500 biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The threshold for renal transplant biopsy should be low, as the procedure is relatively safe as long as the right precautions are taken. The biopsy should be done at a transplant center and read by an experienced transplant pathologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link&amp;anchor=H9#H9\">",
"     \"Indications for and complications of renal biopsy\", section on 'Prebiopsy evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability to predict the cause of allograft dysfunction without a biopsy is notoriously low. Any unexplained increase in creatinine or development of proteinuria merits at the very least discussion of an allograft biopsy with the transplant specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669106\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients develop diabetes mellitus following a renal transplant. This was formerly called post-transplant diabetes (PTDM) but is more recently termed new-onset diabetes after transplantation (NODAT).",
"   </p>",
"   <p>",
"    Reasons for relatively high incidence of NODAT include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The new kidney metabolizes and excretes insulin more efficiently than the failing native kidneys",
"     </li>",
"     <li>",
"      The transplanted kidney is gluconeogenic",
"     </li>",
"     <li>",
"      The immunosuppression regimen is diabetogenic",
"     </li>",
"     <li>",
"      Pre-existing risk factors (such as genetic risk factors or metabolic syndrome) predispose patients to developing diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diabetes most commonly develops within the first few months post transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/20\">",
"     20",
"    </a>",
"    ], although there is continued risk for the life of the patient and allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. We check a fasting blood glucose weekly for the first four weeks following transplantation. A fasting blood glucose and HbA1C are checked at 3, 6, and 12 months following transplantation and annually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/23\">",
"     23",
"    </a>",
"    ]. Many centers rely on blood glucose monitoring and only check HbA1C levels in patients with demonstrated abnormal blood sugars. An elevated HbA1C level should be confirmed by repeat testing. Treatment should be initiated to target glycemic goals defined by the American Diabetes Association (ADA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients will require pharmacologic treatment of hyperglycemia in addition to diet modifications, exercise, and weight loss. The treatment of hyperglycemia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link&amp;anchor=H24#H24\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For some patients, the immunosuppression regimen may be altered or reduced to minimize the risks of diabetic complications; in other cases, oral agents or insulin regimens will need to be implemented to properly control glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/24\">",
"     24",
"    </a>",
"    ]. Steroids, calcineurin inhibitors and MTOR inhibitors can all adversely affect blood glucose levels. Decreasing or eliminating these drugs when possible will help with abnormal blood sugar levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669113\">",
"    <span class=\"h2\">",
"     Infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are a major cause of death following renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/25\">",
"     25",
"    </a>",
"    ]. Transplant patients are susceptible to both common and opportunistic infections.",
"   </p>",
"   <p>",
"    Infections are most likely to occur between the first and third months following transplant, since immune suppression is at its maximum during this time due to induction therapy and pulse steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/26\">",
"     26",
"    </a>",
"    ]. However the risk of infection persists as long as the patient is on immunosuppressive medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669120\">",
"    <span class=\"h3\">",
"     Common infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the general adult population, common infections that occur in transplant patients who are six months or more from transplant include upper respiratory tract infections, and urinary tract infections. A complete differential diagnosis of infections that occur in renal transplant patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=see_link&amp;anchor=H3#H3\">",
"     \"Differential diagnosis of infection following renal transplantation\", section on 'One to six months after transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=see_link&amp;anchor=H4#H4\">",
"     \"Differential diagnosis of infection following renal transplantation\", section on 'Late posttransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12849595\">",
"    <span class=\"h4\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients who have signs or symptoms that suggest common upper respiratory infections (such as the common cold, pharyngitis, influenza) is the same as for the general population. A chest x-ray is generally not indicated unless atypical symptoms (such as dyspnea) or signs (such as localized crackles on auscultation) are present. Patients who appear disproportionately ill, have atypical signs and symptoms or who have a prolonged recovery should be referred back to the transplant physician for further evaluation.",
"   </p>",
"   <p>",
"    Although over-the-counter medications are generally permitted, decongestants and nonsteroidal antiinflammatory agents should be avoided in hypertensive patients because they are vasoconstrictive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12849610\">",
"    <span class=\"h4\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infections are among the most common bacterial infections occurring in the renal transplant recipient. The management of urinary tract infections is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20579?source=see_link\">",
"     \"Urinary tract infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3167713\">",
"    <span class=\"h2\">",
"     Opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the growing population of immunosuppressed patients with prolonged survival, an increased incidence and spectrum of opportunistic infections is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Guidelines for the diagnosis and treatment of infection in transplant recipients have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common pathogens that affect renal transplant recipients include cytomegalovirus (CMV), polyomavirus (BK and JC virus) and increasingly rarely, pneumocystis jirovecii pneumonia (PCP). These are all discussed elsewhere and links are provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3167980\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should not be given any live or live attenuated vaccines after transplantation (",
"    <a class=\"graphic graphic_table graphicRef72071 \" href=\"UTD.htm?29/30/30187\">",
"     table 3",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Varicella zoster",
"     </li>",
"     <li>",
"      Intranasal influenza",
"     </li>",
"     <li>",
"      BCG",
"     </li>",
"     <li>",
"      Live oral typhoid",
"     </li>",
"     <li>",
"      Measles",
"     </li>",
"     <li>",
"      Mumps",
"     </li>",
"     <li>",
"      Rubella",
"     </li>",
"     <li>",
"      Oral polio",
"     </li>",
"     <li>",
"      Live Japanese B encephalitis vaccine",
"     </li>",
"     <li>",
"      Yellow fever",
"     </li>",
"     <li>",
"      Smallpox",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inactivated vaccinations are considered to be safe. The safety of vaccines for household contacts of kidney transplant recipients is vaccine-specific. This issue and specific guidelines for vaccination of transplant recipients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669155\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are inevitably anemic immediately before and after renal transplantation due primarily to surgical blood loss and inflammation with contributing effects of delayed graft function, induction and immunosuppression therapy causing bone marrow suppression, and the abrupt cessation of erythropoietin-stimulating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41433?source=see_link\">",
"     \"Anemia and the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia resolves within 6 to 12 months after transplantation (or earlier among patients who are not iron deficient or have graft dysfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. Anemia may redevelop late in the transplant period in association with decreased transplant function, immunosuppressive drugs, antiviral agents, infections, and the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41433?source=see_link\">",
"     \"Anemia and the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be screened for persistent anemia. In general, a complete blood count is obtained with monitoring labs. (See",
"    <a class=\"local\" href=\"#H25669040\">",
"     'Routine follow up and laboratory monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a patient with previously stable blood counts, if no obvious cause for anemia is found, such as worsening renal function or recent introduction of ACEI or ARB, the patient should be evaluated further for the cause of anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H28#H28\">",
"     \"Approach to the adult patient with anemia\", section on 'Initial approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of anemia for recipients of renal transplant is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41433?source=see_link\">",
"     \"Anemia and the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12851217\">",
"    <span class=\"h2\">",
"     Cardiovascular disease (CVD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is the major cause of death and graft loss in diabetic renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. Risk factors for CVD include end-stage renal disease, diabetes, hypertension, anemia, and obesity; many of these risk factors are caused or exacerbated by immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669169\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, defined as blood pressure greater than",
"    <span class=\"nowrap\">",
"     140/90,",
"    </span>",
"    is reported in 50 to 80 percent of the kidney transplant population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. It is likely to be even more common using the more rigorous blood pressure goal of",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    that is suggested by consensus guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link&amp;anchor=H1#H1\">",
"     \"Hypertension after renal transplantation\", section on 'Introduction'",
"    </a>",
"    .) The presence of hypertension is associated with worse long-term graft outcome including graft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/45\">",
"     45",
"    </a>",
"    ]. Calcineurin inhibitors and steroids contribute to hypertension by causing vasoconstriction and salt retention, weight gain and a mineralocorticoid effect, respectively.",
"   </p>",
"   <p>",
"    The optimal therapy and blood pressure goals in the transplant recipient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=see_link\">",
"     \"Hypertension after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669176\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemia is common among kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/5\">",
"     5",
"    </a>",
"    ] and is a major risk factor for both cardiovascular disease (CVD) and reduced renal allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/46\">",
"     46",
"    </a>",
"    ]. New onset or worsening dyslipidemia has been associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , calcineurin inhibitors and steroid use. The KDOQI guidelines recommend that all adult and adolescent transplant recipients be tested for dyslipidemia (complete fasting lipid profile including total cholesterol, LDL, HDL, and triglycerides) within six months of transplant, at one-year post transplant, and annually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid abnormalities after renal transplantation\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally screen individuals for dyslipidemias at the time of transplant evaluation, upon presentation for transplantation, and quarterly thereafter.",
"   </p>",
"   <p>",
"    The goals of treatment and choice of therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669183\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty percent of transplant patients may be classified as obese or morbidly obese [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/48\">",
"     48",
"    </a>",
"    ]. Diet and exercise are still the mainstays in lifestyle modification for these patients. Weight loss programs should initially be based around diet and exercise. If safe, reduction in the dose of steroids should also be considered, although there is little evidence that reducing chronically administered steroid dosages will result in weight loss and late steroid withdrawal may be associated with development of subclinical rejection.",
"   </p>",
"   <p>",
"    Some patients may use antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ), herbal remedies (such as St. John's wort) and oral weight loss medications (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    ). These medications may interact with the cytochrome P450 pathway and reduce the efficacy of calcineurin inhibitors. We recommend NOT using such agents for transplant recipients",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669190\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplant recipients are approximately three times more likely to develop cancers than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should have the same routine cancer screenings as those recommended for the general population, with exception of skin cancer screening, which is discussed in the next section. The individual's cancer risk, existing comorbidities, overall life expectancy, and preference for screening should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25669197\">",
"    <span class=\"h2\">",
"     Skin cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American and European transplantation organizations recommend skin cancer screening in renal transplant individuals using monthly self skin examinations and six-month to yearly total body skin examinations by expert physicians and dermatologists [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/54\">",
"     54",
"    </a>",
"    ]. All transplant recipients should be encouraged to minimize life-long sun exposure and to use ultraviolet light-blocking agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=see_link&amp;anchor=H2294684#H2294684\">",
"     \"Management of skin cancer in solid organ transplant recipients\", section on 'Follow-up and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25670845\">",
"    <span class=\"h2\">",
"     Bone metabolism and disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone disease is common among patients with chronic kidney disease and often persists following renal transplantation. Factors that contribute to post transplant bone disease include pre-transplant renal osteodystrophy, steroids, calcineurin inhibitors, incomplete resolution of hyperparathyroidism, calcium, and vitamin D deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be regularly monitored for hyperparathyroidism, vitamin D deficiency, hypocalcemia, and hyperphosphatemia. (See",
"    <a class=\"local\" href=\"#H25669040\">",
"     'Routine follow up and laboratory monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is known to increase urinary phosphate loss, and some centers choose to monitor calcium and phosphate levels at every visit. Vitamin D deficiency and",
"    <span class=\"nowrap\">",
"     osteopenia/osteoporosis",
"    </span>",
"    are common among transplant recipients and we recommend routine calcium and vitamin D supplementation for transplant recipients. However, vitamin D and calcium supplementation may lead to hypercalcemia among renal transplant recipients because secondary hyperparathyroidism related to chronic kidney disease may not resolve following transplantation.",
"   </p>",
"   <p>",
"    In addition, some clinicians, though not all, monitor bone mineral density in the renal transplant recipient. There are no reliable studies that have shown that low bone mineral density is predictive of adverse outcomes among transplant recipients, and the optimal treatment for transplant recipients who have abnormal or worsening bone mineral density studies is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25670885\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is common among patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/55\">",
"     55",
"    </a>",
"    ]. Fertility is usually improved within just a few months after renal transplantation, although some impairment may persist in men due to persistent reductions in sperm count and altered sperm morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy in a transplant recipient is considered high-risk given the multiple risk factors for both the mother and the developing fetus. The timing of pregnancy following transplantation is important to minimize risks to the mother and fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link&amp;anchor=H10#H10\">",
"     \"Pregnancy in women with underlying renal disease\", section on 'Pregnancy in the renal transplant recipient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Society of Transplantation Consensus Opinion states that the patient can safely proceed with pregnancy providing the following conditions are met [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft function is optimal, defined as a serum creatinine &lt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      (132",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      with &lt;500",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      h protein excretion",
"     </li>",
"     <li>",
"      There are no concurrent fetotoxic infections, such as CMV",
"     </li>",
"     <li>",
"      The patient is not on known teratogenic or fetotoxic medications",
"     </li>",
"     <li>",
"      The immunosuppressive regimen is stable at maintenance levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when these conditions are met, pregnancy presents some risk to the patient and allograft. The major risk to the patient includes the risk of rejection and allograft failure due to changes in metabolism of immunosuppressive medications and increased filtration that occurs during pregnancy.",
"   </p>",
"   <p>",
"    The major risks to the developing fetus include the effect of immunosuppressive medication and risk of transmission of infection. An infectious disease work-up should be done and active CMV infection excluded in order to minimize transmission to the fetus.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H25670910\">",
"     'Immunosuppressive medication during pregnancy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extensive counseling should be employed to address genetics related to the mother's primary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25670910\">",
"    <span class=\"h2\">",
"     Immunosuppressive medication during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medication alterations may be necessary prior to conception. All immunosuppressive medications carry some risk in pregnancy. It is recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and rapamycin be avoided starting six weeks prior to conception secondary to reports of severe structural malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/58,60\">",
"     58,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus consideration of pregnancy requires a frank discussion between the physician and patient. Contraception should be continued until the immunosuppressive regimen has been changed and therapeutic levels have been achieved.",
"   </p>",
"   <p>",
"    Therapeutic drugs should be maintained at pre-pregnancy levels to reduce the risk of rejection. No conclusive studies have been done to see if there is an increase in the metabolism of these medications during pregnancy. Blood drug levels should be monitored monthly and maintained within therapeutic range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25671040\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there have been a number of pregnancies in transplant recipients, there remains an increased risk to the fetus and the mother. The most effective safe form of contraception should be used to avoid unplanned pregnancies in transplant recipients. The optimal form of contraception for transplant recipients is not known. The American Society of Transplantation Consensus conference suggested the use of progestin-only oral contraceptives and",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    formulations providing blood pressure is adequately controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?14/57/15258/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25671032\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal transplantation is the treatment of choice for patients with end-stage renal disease (ESRD). Patients require close follow-up after transplantation since they are on complex immunosuppressive regimens that render them susceptible to infection, malignancy and cardiovascular disease. In addition, patients often have multiple co-morbidities due to, or as a cause of, their underlying end-stage renal disease. Specific recommendations regarding frequency of visits and routine laboratory tests are provided. (See",
"      <a class=\"local\" href=\"#H25669033\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25669040\">",
"       'Routine follow up and laboratory monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increase in serum creatinine should be evaluated promptly. Prerenal causes such as volume depletion should first be excluded. Medications should be reviewed and it should be determined whether the patient has missed any doses of their immunosuppressant medications. Laboratory investigation should include a serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      level; a urinalysis to exclude infection; and a blood or urine BK viral load to exclude to BK reactivation. A renal ultrasound and a renal biopsy may be necessary if no obvious cause of the increased creatinine can be found. (See",
"      <a class=\"local\" href=\"#H3166750\">",
"       'Renal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetes mellitus commonly develops within the first few months post transplant but there is continued risk for the life of the patient and transplant. Patients should be screened with a fasting blood glucose weekly for the first four months after transplantation, and then at 3, 6, and 12 months and annually thereafter. An HbA1C is not checked during the first four weeks but is often checked in addition to the fasting blood glucose at 3, 6, and 12 months and annually thereafter. Many centers however rely on blood glucose monitoring and only check HbA1C levels in patients with demonstrated abnormal blood sugars. An elevated HbA1C level should be confirmed by repeat testing. (See",
"      <a class=\"local\" href=\"#H25669106\">",
"       'Diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections such as upper respiratory or urinary tract infections are common in renal transplant recipients. Decongestants and nonsteroidal antiinflammatory agents should be avoided. Patients are also at risk for opportunistic infections including cytomegalovirus (CMV), pneumocystis jiroveci (formerly carinii) pneumonia (PCP), polyomavirus (BK and JC virus). (See",
"      <a class=\"local\" href=\"#H25669113\">",
"       'Infectious diseases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular disease (CVD) is the major cause of death and graft loss in diabetic renal transplant recipients. Potentially modifiable risk factors for CVD such as hypertension, hyperlipidemia and obesity should be addressed. Some risk factors are caused or exacerbated by immunosuppressive medications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=see_link\">",
"       \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12851217\">",
"       'Cardiovascular disease (CVD)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancer is more common among transplant recipients than the general population. Renal transplant patients should have the same routine cancer screenings as those recommended for the general population, except for skin cancer screening which should be done monthly by self skin examinations with total body skin examinations done every six-month to yearly by expert physicians and dermatologists. (See",
"      <a class=\"local\" href=\"#H25669190\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone disease is common following renal transplantation. Patients should be regularly monitored for hyperparathyroidism, vitamin D deficiency, hypocalcemia and hyperphosphatemia. Some, though not all clinicians monitor bone density. (See",
"      <a class=\"local\" href=\"#H25670845\">",
"       'Bone metabolism and disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy in a transplant recipient is considered high-risk. The major risks to the patient include the risk of rejection and allograft failure. The major risks to the developing fetus include the effect of immunosuppressive medication and risk of transmission of infection. All immunosuppressive medications carry some risk in pregnancy; in particular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil and rapamycin should be avoided starting six weeks prior to conception. The most effective safe form of contraception should be used to avoid unplanned pregnancies in transplant recipients. (See",
"      <a class=\"local\" href=\"#H25670885\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/1\">",
"      Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/2\">",
"      Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/3\">",
"      Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/4\">",
"      Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/5\">",
"      Gotti E, Perico N, Perna A, et al. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 2003; 14:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/6\">",
"      Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002; 73:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/7\">",
"      Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/8\">",
"      Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/9\">",
"      Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/10\">",
"      Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/11\">",
"      Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/12\">",
"      Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/13\">",
"      Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/14\">",
"      Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005; 80:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/15\">",
"      Hohage H, Kleyer U, Br&uuml;ckner D, et al. Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron 1997; 75:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/16\">",
"      Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/17\">",
"      Fern&aacute;ndez-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002; 73:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/18\">",
"      Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003; 76:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/19\">",
"      Schwarz A, Gwinner W, Hiss M, et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/20\">",
"      Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/21\">",
"      Woodward RS, Flore MC, Machnicki G, Brennan DC. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. Value Health 2011; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/22\">",
"      Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/23\">",
"      Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/24\">",
"      Boots JM, Christiaans MH, Van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/25\">",
"      Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/26\">",
"      Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004; 4 Suppl 10:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/27\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/28\">",
"      Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/29\">",
"      The AST Infectious Disease Community of Practice, Amercian Society of Transplantation, Infectious Disease Guidelines for Transplantation. Am J Transpl 2009; 9 (Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/30\">",
"      Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003; 3:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/31\">",
"      Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/32\">",
"      Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005; 102:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/33\">",
"      Sun CH, Ward HJ, Paul WL, et al. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989; 321:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/34\">",
"      Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/35\">",
"      Afzali B, Al-Khoury S, Shah N, et al. Anemia after renal transplantation. Am J Kidney Dis 2006; 48:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/36\">",
"      Chadban SJ, Baines L, Polkinghorne K, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis 2007; 49:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/37\">",
"      Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2007.",
"    </li>",
"    <li>",
"     USRDS: Annual Data Report: Atlas of End Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/40\">",
"      Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/41\">",
"      Aakhus, S, Dahl, K, Wideroe, TE. Cardiovascular morbidity and mortality in renal transplant recipients. Nephrol Dial Transplant 1997; 12:A231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/42\">",
"      Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/43\">",
"      Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/44\">",
"      Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/45\">",
"      Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/46\">",
"      Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/47\">",
"      Kasiske BL, K/DOQI Dyslipidemia Work Group. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant 2005; 5:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/48\">",
"      Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/49\">",
"      Barbaro D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002; 8:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/50\">",
"      Ernst E. St John's Wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/51\">",
"      Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/52\">",
"      Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/53\">",
"      Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol 2008; 3 Suppl 2:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/54\">",
"      EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.2. Cancer risk after renal transplantation. Skin cancers: prevention and treatment. Nephrol Dial Transplant 2002; 17 Suppl 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     McKay, DB, Josephson, MA. Pregnancy after kidney transplantation. Clin J Am Soc Nephrol 2008; 3 Suppl 2:S117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/56\">",
"      Davison JM. Dialysis, transplantation, and pregnancy. Am J Kidney Dis 1991; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/57\">",
"      First MR, Combs CA, Weiskittel P, Miodovnik M. Lack of effect of pregnancy on renal allograft survival or function. Transplantation 1995; 59:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/58\">",
"      Akbari F, Alavi M, Esteghamati A, et al. Effect of renal transplantation on sperm quality and sex hormone levels. BJU Int 2003; 92:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/59\">",
"      McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant 2005; 5:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/57/15258/abstract/60\">",
"      EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 2002; 17 Suppl 4:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14039 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15258=[""].join("\n");
var outline_f14_57_15258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25671032\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25669033\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25669040\">",
"      ROUTINE FOLLOW UP AND LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3167242\">",
"      MANAGEMENT OF IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3167267\">",
"      Toxicity associated with common immunosuppressive regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3167274\">",
"      Abnormal calcineurin inhibitor concentrations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155049\">",
"      COMMON MEDICAL PROBLEMS FOLLOWING TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3166750\">",
"      Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1986915\">",
"      - Increased creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669071\">",
"      - Microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669078\">",
"      - Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25669106\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25669113\">",
"      Infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669120\">",
"      - Common infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12849595\">",
"      Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12849610\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3167713\">",
"      Opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3167980\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25669155\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12851217\">",
"      Cardiovascular disease (CVD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669169\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669176\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25669183\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25669190\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25669197\">",
"      Skin cancer screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25670845\">",
"      Bone metabolism and disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25670885\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25670910\">",
"      Immunosuppressive medication during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25671040\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25671032\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/14039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/14039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/6/31851\" title=\"table 1\">",
"      Frequency of laboratory tests following kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/45/29403\" title=\"table 2\">",
"      Effect of drugs on calcineurin inhibitor concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/30/30187\" title=\"table 3\">",
"      Recommended immunizations for kidney transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41433?source=related_link\">",
"      Anemia and the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=related_link\">",
"      Anti-GBM antibody disease: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1625?source=related_link\">",
"      Hepatitis B virus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39367?source=related_link\">",
"      IgA nephropathy: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32614?source=related_link\">",
"      Membranoproliferative glomerulonephritis: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34088?source=related_link\">",
"      Membranous nephropathy and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20579?source=related_link\">",
"      Urinary tract infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21577?source=related_link\">",
"      Withdrawal or avoidance of glucocorticoids after renal transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_57_15259="Rx genital warts";
var content_f14_57_15259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for genital warts*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichloroacetic or bichloroacetic acid, or podophyllin&bull; or liquid nitrogen one to two times weekly until resolved",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imiquimod 5 percent&bull; three times weekly for 16 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Podofilox 0.5 percent&bull; twice daily for three days, four days rest, then repeated up to four times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laser surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intralesional interferon",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The above recommendations are only for external genital warts. Liquid nitrogen can also be used for vaginal, urethral, and oral warts. Podofilox or imiquimod can be used for urethral meatus warts. Trichloroacetic or bichloroacetic acid can be used for anal warts.",
"     <br>",
"      &bull; Not recommended in pregnancy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Drugs for sexually transmitted diseases. Treat Guidel Med Lett 2004; 2:67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15259=[""].join("\n");
var outline_f14_57_15259=null;
var title_f14_57_15260="Poser criteria for MS";
var content_f14_57_15260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Poser diagnostic criteria for multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinically definite multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Two attacks plus two separate clinical lesions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Two attacks plus one clinical lesion plus another separate paraclinical lesion",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory supported definite multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Two attacks plus one clinical lesion plus CSF, OCB, or IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Two attacks plus one paraclinical lesion plus CSF, OCB, or IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. One attack plus two separate clinical lesions plus CSF, OCB, or IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. One attack plus one clinical lesion plus one paraclinical lesion plus CSF, OCB, or IgG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clincally probably multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Two attacks plus one clinical lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. One attack plus two separate clinical lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. One attack plus one clinical lesion plus one paraclinical lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory supported probable multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Two attacks plus CSF, OCB, or IgG",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid; OCB: oligoclonal banding; IgG: Immunoglobulin G.",
"     <br>",
"      * Clinical lesion: lesion detected on history and physical examination.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Paraclinical lesion: lesion detected by evoked response testing, MRI, or urodynamic studies.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Poser CM, Paty DW, Scheinberg L, et al, Ann Neurol 1983; 13:227.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15260=[""].join("\n");
var outline_f14_57_15260=null;
var title_f14_57_15261="Natural history diverticulosis";
var content_f14_57_15261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natural history of diverticulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 205px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15261=[""].join("\n");
var outline_f14_57_15261=null;
var title_f14_57_15262="Comparison of aerosol devices";
var content_f14_57_15262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52016%7EPULM%2F71527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52016%7EPULM%2F71527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of pressurized metered dose inhalers with holding chamber, dry powder inhalers, and nebulizers as aerosol delivery devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        pMDI/HC",
"       </td>",
"       <td class=\"subtitle1\">",
"        DPIs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nebulizer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Majority of aerosol particles &lt;5 &micro;m in size",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High pulmonary deposition",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low mouth deposition",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reliability of dose",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenced by humidity",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Physical and chemical stability",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breath actuated",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Risk of contamination",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Convenience",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lightweight, compact",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple doses",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dose counter",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Easy and quick operation",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suitable for all ages",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DPI: dry power inhaler; pMDI: pressurized metered-dose inhalers; HC: holding chamber.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, BK, Fink, JB. Aerosol therapy for children. Respir Care Clin N Am 2001; 7:175. Copyright &copy; 2001 Elsevier Science (USA).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of various aerosol devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jet nebulizer*",
"       </td>",
"       <td>",
"        <p>",
"         Patient coordination not required",
"        </p>",
"        <p>",
"         High doses possible",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Generally more expensive than metered dose inhaler",
"        </p>",
"        <p>",
"         More time required",
"        </p>",
"        <p>",
"         Contamination possible",
"        </p>",
"        <p>",
"         Device preparation required before treatment",
"        </p>",
"        <p>",
"         Not all medications available",
"        </p>",
"        <p>",
"         Less efficient than other devices (dead volume loss)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mesh nebulizer (eg, Aeroneb",
"        <sup>",
"         &reg;",
"        </sup>",
"        , eFlow",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Omron MicroAir",
"        <sup>",
"         &reg;",
"        </sup>",
"        , I-neb)",
"       </td>",
"       <td>",
"        <p>",
"         Patient coordination not required",
"        </p>",
"        <p>",
"         High doses possible",
"        </p>",
"        <p>",
"         Quiet",
"        </p>",
"        <p>",
"         Faster delivery than jet nebulizer",
"        </p>",
"        <p>",
"         More accurate delivery of desired dose than jet nebulizer",
"        </p>",
"        <p>",
"         Portable, battery operated",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Expensive",
"        </p>",
"        <p>",
"         Contamination possible",
"        </p>",
"        <p>",
"         Device preparation required before treatment",
"        </p>",
"        <p>",
"         Cleaning required after dose",
"        </p>",
"        <p>",
"         Not all medications available",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ultrasonic nebulizer (eg, OPTI-NEB&trade;, Beetle Neb, Lumiscope, MiniBreeze)",
"       </td>",
"       <td>",
"        <p>",
"         Patient coordination not required",
"        </p>",
"        <p>",
"         High doses possible",
"        </p>",
"        <p>",
"         Small dead volume",
"        </p>",
"        <p>",
"         Quiet",
"        </p>",
"        <p>",
"         No drug loss during exhalation",
"        </p>",
"        <p>",
"         Faster delivery than jet nebulizer",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Expensive",
"        </p>",
"        <p>",
"         Contamination possible",
"        </p>",
"        <p>",
"         Prone to malfunction",
"        </p>",
"        <p>",
"         Device preparation required before treatment",
"        </p>",
"        <p>",
"         Cannot use with medications in suspension (eg, budesonide)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Metered-dose inhaler",
"       </td>",
"       <td>",
"        <p>",
"         Convenient",
"        </p>",
"        <p>",
"         Less expensive than nebulizer",
"        </p>",
"        <p>",
"         Portable",
"        </p>",
"        <p>",
"         More efficient than nebulizer",
"        </p>",
"        <p>",
"         No drug preparation required",
"        </p>",
"        <p>",
"         Difficult to contaminate",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Patient coordination essential",
"        </p>",
"        <p>",
"         Patient actuation required",
"        </p>",
"        <p>",
"         Large pharyngeal deposition",
"        </p>",
"        <p>",
"         Difficult to deliver high doses",
"        </p>",
"        <p>",
"         Not all medications available",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Metered-dose inhaler with holding chamber",
"       </td>",
"       <td>",
"        <p>",
"         Less patient coordination required",
"        </p>",
"        <p>",
"         Less pharyngeal deposition",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         More expensive than MDI alone",
"        </p>",
"        <p>",
"         Less portable than MDI alone",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dry powder inhaler",
"       </td>",
"       <td>",
"        <p>",
"         Less patient coordination required",
"        </p>",
"        <p>",
"         Convenient",
"        </p>",
"        <p>",
"         Propellant not required",
"        </p>",
"        <p>",
"         Portable",
"        </p>",
"        <p>",
"         Breath-actuated",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Requires moderate to high inspiratory flow",
"        </p>",
"        <p>",
"         Some units are single dose",
"        </p>",
"        <p>",
"         Can result in high pharyngeal deposition",
"        </p>",
"        <p>",
"         Not all medications available",
"        </p>",
"        <p>",
"         Difficult to deliver high doses",
"        </p>",
"        <p>",
"         Cannot use with endotracheal or tracheostomy tubes",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CFC: chlorofluorocarbon; MDI: metered-dose inhaler.",
"     <br>",
"      * Many brands are commercially available in both disposable and non-disposable designs for use in the hospital and at home.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Consensus Statement: Aerosols and Delivery Devices. Respir Care 2000; 45:589.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_57_15262=[""].join("\n");
var outline_f14_57_15262=null;
var title_f14_57_15263="Contents: Lung cancer";
var content_f14_57_15263=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lung cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lung cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis and staging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8474\">",
"           Clinical presentation and management of thymoma and thymic carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17080\">",
"           Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14841\">",
"           Diagnosis and staging of non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44537\">",
"           Diagnostic evaluation and management of the solitary pulmonary nodule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21511\">",
"           Fluorescence bronchoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6759\">",
"           Multiple primary lung cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/61/13273\">",
"           Overview of the initial evaluation, treatment and prognosis of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42552\">",
"           Pathobiology and staging of small cell carcinoma of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/10/19625\">",
"           Role of imaging in the staging of non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28586\">",
"           Screening for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/28/28102\">",
"           Thoracic positron emission tomography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/35/3642\">",
"           Transbronchial needle aspiration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/21/44373\">",
"           Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12298\">",
"           Cigarette smoking and other risk factors for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mediastinal tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/40/32392\">",
"           Anterior mediastinal mass lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/24/31111\">",
"           Evaluation of mediastinal masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/52/10058\">",
"           Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/43/4794\">",
"           Pathology of mediastinal tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mesothelioma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/50/32552\">",
"           Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7622\">",
"           Epidemiology of malignant mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29204\">",
"           Pathology of malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/21/42329\">",
"           Systemic treatment for unresectable malignant pleural mesothelioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/41/28312\">",
"           Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/45/9946\">",
"           Bronchioloalveolar carcinoma, including adenocarcinoma in situ",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/44/8902\">",
"           Chemoprevention of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12394\">",
"           Lung cancer in never smokers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/58/14250\">",
"           Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10821\">",
"           Tracheal tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/43/22201\">",
"           Pathology of lung malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/28/21962\">",
"           Thymic neuroendocrine (carcinoid) tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17833\">",
"           Adjuvant systemic therapy in resectable non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/34/9768\">",
"           Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34823\">",
"           Airway stents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40440\">",
"           Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38292\">",
"           Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/13/10453\">",
"           Bronchoscopic cryosurgery: Principles and technique",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/47/38645\">",
"           Bronchoscopic laser resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9914\">",
"           Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/17/8474\">",
"           Clinical presentation and management of thymoma and thymic carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20900\">",
"           Cryoablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37351\">",
"           Diagnosis and management of central airway obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/18/32038\">",
"           Endobronchial brachytherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11447\">",
"           Endobronchial electrocautery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8951\">",
"           Experimental approaches to treatment for small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/52/10058\">",
"           Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/39/6778\">",
"           First-line chemotherapy for patients with extensive stage small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/54/34666\">",
"           Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31816\">",
"           Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/6/13416\">",
"           Management of malignant pleural effusions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1114\">",
"           Management of stage I and stage II non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/36/39498\">",
"           Management of stage III non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6759\">",
"           Multiple primary lung cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16282\">",
"           Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/57/21401\">",
"           Overview of the treatment of advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/58/14250\">",
"           Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14809\">",
"           Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37749\">",
"           Photodynamic therapy of lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15400\">",
"           Preoperative evaluation for lung resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1830\">",
"           Prophylactic cranial irradiation for patients with small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/42/25255\">",
"           Radiofrequency ablation of lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38469\">",
"           Role of surgery in multimodality therapy for small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/36/40520\">",
"           Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32329\">",
"           Sequelae and complications of pneumonectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17143\">",
"           Stereotactic body radiation therapy for primary and metastatic lung tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36455\">",
"           Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26199\">",
"           Systemic therapy for poor performance status patients with advanced non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/5/4183\">",
"           Treatment of refractory and relapsed small cell lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-54896E625D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_57_15263=[""].join("\n");
var outline_f14_57_15263=null;
